Genetically engineered mouse models of breast carcinoma: a translational resource for highlighting human breast subtype etiology and developing personalized therapeutic approaches by Pfefferle, Adam
GENETICALLY ENGINEERED MOUSE MODELS OF BREAST CARCINOMA: 
A TRANSLATIONAL RESOURCE FOR HIGHLIGHTING HUMAN BREAST SUBTYPE 
ETIOLOGY AND DEVELOPING PERSONALIZED THERAPEUTIC APPROACHES 
Adam David Pfefferle 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department 
of Pathology and Laboratory Medicine 
Chapel Hill 
2015 
Approved by: 
Charles M. Perou 
H. Shelton Earp III 
William K. Kaufmann 
Joel S. Parker 
Norman E. Sharpless 
Bernard E. Weissman 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2015 
Adam David Pfefferle 
ALL RIGHTS RESERVED 
iii 
 
ABSTRACT 
Adam David Pfefferle: Genetically engineered mouse models of breast carcinoma: a 
translational resource for highlighting human breast subtype etiology and developing 
personalized therapeutic approaches 
(Under the direction of Charles M. Perou) 
 
Approximately one in eight women will be diagnosed with breast cancer during their 
lifetime. While increased public awareness has led to earlier detection of this common disease, 
a greater understanding of tumor biology has led to the development of many promising 
therapeutics. A difficult frontier, however, has been identifying the appropriate target 
population for new drugs as not all breast cancer patients will respond to a particular 
therapeutic. Currently, approximately five percent of oncology drugs that enter clinical testing 
are ultimately approved by the US Food and Drug Administration for use. This low success 
rate reflects not only the difficulty of developing anticancer therapeutics, but also flaws in 
preclinical testing methodology for selecting the most appropriate cancer patient subset for 
early clinical testing. With so many patients either not responding or relapsing with the current 
standard of care, improved personalized therapeutic approaches are greatly needed. 
Breast cancer is a heterogeneous disease consisting of multiple intrinsic subtypes. Even 
though clear clinical and genetic distinctions between the subtypes have been described, the 
driving mechanisms underlying the initiation, growth and metastasis of breast tumors are 
under intense investigation to more fully characterize these phenotypes since targeted 
treatment against specific aberrations promises to be more effective with less systemic side 
effects. Genetically engineered mouse models are a useful resource for studying mammary 
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cancers in vivo under genetically controlled and immune competent conditions. Identifying 
murine models with conserved human tumor features will not only facilitate etiology 
determinations for the intrinsic subtypes, but also serve as a useful preclinical resource for 
testing the efficacy of new therapeutic approaches. These mice promise to be better predictors 
of clinical trial success because they resemble tumor biology more closely than other 
approaches. The work presented here focuses on determining the degree to which current 
mouse models of breast carcinoma resemble the human disease state and identifies mouse 
model counterparts for each of the human intrinsic subtypes. If these credentialed mouse 
models are used for preclinical testing, we anticipate a higher success rate for the development 
of targeted therapeutics. 
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CHAPTER 1: INTRODUCTION 
 
About three quarters of a million American women were diagnosed with new cases of 
cancer last year [1]. With breast cancer accounting for about thirty percent of these incidences, 
one in eight women will be affected by this common disease in their lifetime [1]. Increased 
public awareness and a greater understanding of tumor biology has led to better patient survival 
rates since the early 1990s, yet this disease is still the second leading cause of cancer related 
deaths in American women [1]. With so many patients either not responding or relapsing with 
the current standard of care, the molecular mechanisms underlying breast cancer are under 
intense investigation to identify new, personalized drug targets that should improve patient 
outcomes [2, 3]. 
 
A greater understanding of breast cancer biology will identify novel therapeutic targets 
Breast cancer is a heterogeneous disease consisting of multiple disease subtypes that are 
referred to as the intrinsic subtypes: luminal A, luminal B, HER2-enriched, basal-like, claudin-
low [4-8]. Tumor subtyping can be performed using two complementary gene expression based 
tests: the PAM50 intrinsic subtyping assay [9] and the claudin-low predictor [6]. Clinically, these 
subtypes are prognostic [5, 7, 9] and predict sensitivity to specific therapeutics [5, 10]. Luminal 
A tumors have the best overall survival, while the other subtypes have similar, poor outcomes if 
untreated [7]. Generally, the luminal A/B subtypes are estrogen receptor positive (ER
+
) and/or 
progesterone receptor positive (PR
+
) tumors [7]. These subtypes also tend to lack the human 
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epidermal growth factor receptor 2 (HER2
-
). Luminal B tumors are distinguishable from the 
luminal A subtype by their faster, more aggressive proliferation rates. HER2-enriched tumors, on 
the other hand, are typically ER
-
, PR
-
, and HER2
+
, with similar high proliferation and low 
survival rates as luminal B tumors when untreated [7]. The remaining two subtypes, basal-like 
and claudin-low, are broadly considered triple negative breast cancer (TNBC) (ER
-
, PR
-
 and 
HER2
-
) [7]. Basal-like breast cancers have the highest proliferation rates and are the most 
genetically unstable of all the subtypes [11, 12]. Claudin-low tumors are characterized by low 
levels of cell adhesion molecules and high levels of inflammatory cells [6]. While targeted 
therapeutics exist for ER
+
 [13] (luminal A/B [14]) and HER2
+
 [15] (HER2-enriched [14]) breast 
cancer, targeted treatments for TNBC (basal-like and claudin-low [14]) remain an important 
unmet clinical need [16]. To address this need, a research emphasis has been placed on 
determining the molecular drivers of basal-like and claudin-low tumors to identify novel drug 
targets for these subtypes, which was an important aspect of my thesis work. 
Even though clear distinctions between the intrinsic subtypes have been defined, the 
molecular mechanisms that give rise to breast tumors in general, and the individual intrinsic 
subtypes, are not fully known. For instance, it is unknown why some tumors of the same subtype 
respond differently to the same therapeutic treatment [3, 17]. A greater knowledge of the 
molecular aberrations underlying breast tumors will identify these differences in genetic drivers, 
which we believe to be the key first step towards personalized drug therapies [3]. Segregating 
genetic drivers from passenger mutations is difficult due to the inherent heterogeneity of breast 
tumors and the large number of genetic aberrations seen within a given tumor. Several 
hypotheses have been described to explain breast cancer heterogeneity. 1) Breast tumors can 
arise from a number of different mature and/or stem cell types, which may form the basis for the 
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intrinsic subtypes [18-21]. 2) Similarly, tumors develop through clonal expansion of evolving 
clones, resulting in intra-tumor pockets of cell colonies containing their own set of aberrations 
[22]. 3) The tumor microenvironment can interact with progressing cancer cells to affect the 
overall tumor phenotype [23, 24]. 4) External factors (e.g. environmental, lifestyle, and 
comorbidity) influence tumor development [25]. All of these factors probably have some role in 
determining the ultimate phenotype of a progressing breast tumor, but more research is needed to 
validate the relative contributions of each. 
Over the last fifteen years, genomics [12, 26] and transcriptomics [4] have fueled a 
greater understanding of breast tumor biology [8]. The cancer genome is broadly characterized as 
unstable. The inability to properly respond to and fix DNA damage leads to the accumulation of 
small scale mutations [26] (e.g. insertions, deletions) and large scale chromosomal 
rearrangements [12] (e.g. translocations, aneuploidy). Microarray and sequencing techniques 
have been developed to identify genomic aberrations that can lead to decreased tumor suppressor 
function, increased oncogene signaling, or both. Transcriptomics (gene expression analysis) is a 
popular approach for characterizing tumors because it is easy to measure, provides a rough 
estimate of corresponding protein levels, and identifies overarching tumor phenotypes. Given the 
large number of transcriptomic studies, the Broad Institute has created the molecular signatures 
database (MSigDB), which compiles gene sets/modules from the literature into one place [27]. 
This database improves on the gene-gene comparison by allowing for the comparison of gene 
groups. While each of these approaches has improved our knowledge of cancer biology by 
themselves, studies integrating multiple 'omic approaches have an even greater power of 
identifying important tumor phenotypes and novel drug targets, with examples being the cancer 
genome atlas’s (TCGA) analysis of glioblastoma and ovarian cancers [28, 29]. 
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Personalized drug regimens are the future of cancer treatment  
Developing clinical tests that predict drug response (i.e. companion diagnostics) is an 
important focus of cancer research. Two clinical trials have brought the use of molecular testing 
to the forefront of breast cancer research. In these trials, the Oncotype DX
TM
 (TAILORx trial) 
[30] and MammaPrint
TM
 (MINDACT trial) [31] assays are being used to determine which 
patients should receive chemotherapy. A recent comparison of Oncotype DX
TM
 with the PAM50 
intrinsic subtyping assay identified that the PAM50 risk of recurrence (ROR) as superior to the 
Oncotype DX
TM
 recurrence score (RS) in endocrine-treated patients with ER-positive, node-
negative disease [32]. While the use of molecular testing in the clinic has been groundbreaking, 
these assays do not identify which drug regimens to prescribe. Clinical assays that determine 
personalized drug regimens are greatly needed to improve patient survival. 
Before personalized drug testing can begin in the clinic, the target population for 
molecularly targeted drugs needs to be identified. This is a difficult task, but is critical for 
developing the best predictors of response. Targeted cancer drugs are designed to inhibit specific 
genetic aberrations, typically kinases or hormone receptors, but not all tumors with the aberration 
respond to treatment [17]. Additional factors (e.g. coexisting aberrations, cell of origin, 
microenvironment) are hypothesized to confer sensitivity or resistance to drug treatment [33-36]. 
Even though studies have defined predictive signatures of response [37-41], most are not 
reproducible [42, 43]. Many of these predictive signatures were derived under very specific 
conditions (e.g. using one cell line), so while they might work in a specific limited setting, they 
typically fail when applied to a broad population of patients [44]. Clinical tumors are highly 
heterogeneous; therefore, predictive signatures should be tested under heterogeneous conditions 
and across multiple models. This thesis was in part focused on characterizing the wealth of 
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mouse models of human breast cancer such that this heterogeneous set of models could be better 
linked to human breast tumors, which we predict would then help drug testing and development. 
 
Murine models are excellent for translating biological discovery into clinical care  
Currently, only ~5% of oncology drugs that enter clinical testing are approved by the 
FDA for use [45]. This dismal success rate not only reflects the difficulty of developing 
anticancer therapeutics, but also flaws in preclinical methodology for selecting the most 
promising drugs to use in clinical trials [43, 46]. Historically, preclinical drug testing has 
primarily involved a mix of in vitro cell line and in vivo cell line xenograft experiments. While 
these studies are a good first step, they do not represent true tumor biology [47]. For instance, the 
few cell lines available for use have limited biological diversity when compared to primary 
tumors, and they represent a subset of the original clones with the best growth advantages. These 
cell line based approaches are unable to accurately represent clinical heterogeneity or an intact 
microenvironment, and as a result, many of the drugs that pass cell line based preclinical testing 
fail during later stages.  
Even though they have existed for decades, genetically engineered mouse models 
(GEMMs) have only recently become a more popular system for preclinical drug testing [47]. 
While cross-species complications do exist, these mice promise to be better predictors of clinical 
trial success because they resemble tumor biology more closely than xenografts. This is most 
evident from treatment experiments showing that tumors within a murine model vary in their 
drug response [48]. This response spectrum resembles the results from human trials more than 
the typical uni-modal response of cell line-based xenograft studies. These early observations 
indicate a strong need for murine models in preclinical testing. 
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Comparative studies between human and murine tumors provide an attractive approach 
for narrowing the genetic driver candidate list by highlighting conserved features between 
species [49] and thus focusing attention on the most likely driver genes. While dozens of murine 
models have been created to study the molecular mechanisms of breast cancer [50-56], the 
degree to which many of these models recapitulate the human subtypes is largely unknown. 
Before proper therapeutic comparative studies can be performed, it is essential that human-to-
murine tumor counterparts are identified to ensure that the chosen model accurately replicates 
the genetic alterations and overall phenotypes observed in human tumors [49]. This is especially 
important for heterogeneous human diseases, such as breast cancer. 
Given the advantages of murine models for studying tumorigenesis [47], the following 
four chapters utilize genetically engineered mouse model of breast carcinoma to simultaneously 
investigate human tumor etiology and as a tool for preclinical drug testing. Chapter 1, which was 
published in Genome Biology in 2013 [49], analyzes the transcriptomic profiles of 27 murine 
models to highlight the subset of GEMMs that mimic the human disease state. Chapter 2, which 
was published in Breast Cancer Research and Treatment in 2015 [57], analyzes the 
transcriptomic profiles of normal mammary cell types to highlight conserved cell features 
between human-murine subtype counterparts. In addition, this study identifies several gene 
signatures that predict tumor pathologic complete response sensitivity to neoadjuvant 
chemotherapy even after controlling for intrinsic subtype, proliferation, and clinical variables. 
Chapter 3 analyzes the secondary genetic aberrations of p53null mammary transplant murine 
tumors, highlighting MET as a genetic driver of murine basal-like tumors. Chapter 4 investigates 
the phenotypic and clinical differences between the MMTV-Wnt1 tumor subtypes, highlighting 
EGFR as a potential drug target in breast tumors with aberrant Wnt signaling.  
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CHAPTER 2: TRANSCRIPTOMIC CLASSIFICATION OF GENETICALLY 
ENGINEERED MOUSE MODELS OF BREAST CANCER IDENTIFIES HUMAN 
SUBTYPE COUNTERPARTS
1 
 
OVERVIEW 
Background 
Human breast cancer is a heterogeneous disease consisting of multiple molecular 
subtypes. Genetically engineered mouse models are a useful resource for studying mammary 
cancers in vivo under genetically controlled and immune competent conditions. Identifying 
murine models with conserved human tumor features will facilitate etiology determinations, 
highlight the effects of mutations on pathway activation, and should improve preclinical drug 
testing. 
 
Results 
Transcriptomic profiles of 27 murine models of mammary carcinoma and normal 
mammary tissue were determined using gene expression microarrays. Hierarchical clustering 
analysis identified 17 distinct murine subtypes. Cross-species analyses using three 
independent human breast cancer datasets identified eight murine classes that resemble 
specific human breast cancer subtypes. Multiple models were associated with human basal-
like tumors including TgC3(1)-Tag, TgWAP-Myc and Trp53
−/−
. Interestingly, the 
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TgWAPCre-Etv6 model mimicked the HER2-enriched subtype, a group of human tumors 
without a murine counterpart in previous comparative studies. Gene signature analysis 
identified hundreds of commonly expressed pathway signatures between linked mouse and 
human subtypes, highlighting potentially common genetic drivers of tumorigenesis. 
 
Conclusions 
This study of murine models of breast carcinoma encompasses the largest 
comprehensive genomic dataset to date to identify human-to-mouse disease subtype 
counterparts. Our approach illustrates the value of comparisons between species to identify 
murine models that faithfully mimic the human condition and indicates that multiple mouse 
models are needed to represent the diversity of human breast cancers. The reported trans-
species associations should guide model selection during preclinical study design to ensure 
appropriate representatives of human disease subtypes are used. 
 
BACKGROUND 
Breast cancer is the second leading cause of cancer related deaths in American 
women [1]. While increased public awareness has led to earlier detection, a greater 
understanding of tumor biology has led to the development of many promising therapeutics 
[2, 3]. A difficult frontier, however, has been identifying the appropriate target population for 
new drug(s) as not all breast cancer patients will respond to a particular therapeutic. 
Currently, only approximately five percent of oncology drugs that enter clinical testing are 
ultimately approved by the US Food and Drug Administration for use [4]. This low success 
rate reflects not only the difficulty of developing anticancer therapeutics, but also identifies 
14 
 
flaws in preclinical testing methodology for selecting the most appropriate cancer patient 
subset for early clinical testing [5, 6]. 
Numerous murine models of breast cancer have been created to mimic the genetic 
aberrations found in human tumors [7-30]. Historically, each model has been analyzed 
independent of other models, which complicates effective comparisons with human tumors. 
However, when multiple models are consolidated into a single dataset, there is increased 
sensitivity to detect features that are conserved with the human disease state [31, 32]. 
Identifying murine models that faithfully mimic specific human breast cancer subtypes [33-
35] is an important need for the proper interpretation of mouse model results, and thus, for 
translating preclinical findings into effective human clinical trials [36]. To address this need, 
we used a transcriptomic approach to profile tumors from 27 different genetically engineered 
mouse models (GEMMs). We define and characterize 17 distinct murine subtypes of 
mammary carcinoma (referred to as classes herein to distinguish them from the human 
subtypes), which we compare to three human breast tumor datasets comprising over 1700 
patients to determine which GEMM classes resemble specific human breast cancer subtypes. 
 
RESULTS 
Expression classes of genetically engineered mouse models 
As the genetic aberrations of human breast cancers have been elucidated, murine 
models have been created to investigate the specific role that these genes/proteins have on 
tumor phenotype. Since our initial comparative genomics study of 14 mouse models and 
normal mammary tissue [31], the number of breast cancer GEMMs in our database has 
roughly doubled to 27 (Table 1). To compare the transcriptomic diversity of these GEMMs,  
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Table 1: Summary of murine models studied  
A complete list of all GEMMs used. The bottom 15 models/normal mammary were studied 
by Herschkowitz et al. 2007. C3(1), 5' flanking region of the C3(1) component of the rat 
prostate steroid binding protein. MMTV, mouse mammary tumor virus. WAP, whey acidic 
protein. 
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Figure 1: Flowchart of murine expression data analysis  
Agilent microarrays from three different platforms were normalized and combined together 
to create a single murine expression dataset. Next, an unsupervised cluster analysis using 
variably expressed genes was performed to define a murine ‘intrinsic gene list’. Third, this 
intrinsic list was used as part of a supervised cluster analysis to objectively define murine 
subtypes/classes. Fourth, class based supervised analyses were used to define murine class 
specific lists (genes and pathways). Finally, supervised comparative analysis between human 
subtypes and mouse classes was used to identify and characterize human-mouse counterparts. 
Key: NF – normalization factor 
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global gene expression measurements from 356 unique murine tumors and 16 normal murine 
mammary samples were analyzed using Agilent microarrays (see Table 1A, Figure 1). Using 
this larger and more diverse murine dataset, a new mouse ‘intrinsic gene list’ was derived to 
identify genes associated with all 27 models. As expected, many of the genes from the 
previous intrinsic gene list were also present in the updated list. After filtering for genes 
found in both datasets, 76.5% (500/654) of the intrinsic probes from Herschkowitz et al 2007 
were again included within the new intrinsic list of 1855 probes, which represents 1841 
genes. 
To determine if new murine subtypes/classes exist in this expanded dataset, SigClust 
analysis [37] was performed using supervised hierarchical clustering of the 385 murine 
microarrays and the intrinsic 1855 probe list (Figure 2). Murine ‘classes’ were defined as 
having at least five tumors with a SigClust p-value ≤ 0.01. Using these criteria, 17 murine 
classes were identified with 94% (363/385) of tumors being included within one of these 
classes (Figure 2B and Figure 3). The name for each class was determined based upon the 
major model contributor (e.g. Myc
Ex
), the major biological feature (e.g. Squamous-like
Ex
), or 
both (e.g. p53null-Basal
Ex), with the ‘Ex’ designation used to denote that this is an expression-
based class. As previously observed [31], the Brca1
+/-
 Trp53
+/-
 irradiated, TgC3(1)-Tag, 
TgMMTV-Neu, TgWAP-Int3, TgWAP-Myc, and TgWAP-Tag murine models have 
‘homogeneous’ gene expression patterns in this dataset; here, a model was considered 
‘homogenous’ if ≥ 80% of tumors from that GEMM were found within a single expression-
defined class (Table 1B and Figure 4). Many of the newest models also showed 
homogeneous gene expression patterns including Stat1
-/-
, TgMMTV-Myc, TgMMTV-
Wnt1/iFGFR2, and TgWAPCre-Etv6. 
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Figure 2: Murine intrinsic class analysis  
A. Supervised cluster using the newly derived murine intrinsic gene list and all murine arrays 
in the dataset. Roman numerals next to the gray bars correspond to the enlarged regions in 
parts i-v. B. Dendrogram of the cluster from part A with the murine classes identified by 
SigClust highlighted. Classes with colored boxes have been determined to be human 
expression-based subtype counterparts. C. Breast cancer genes and individual cell lineage 
marker expression profiles. i. Claudin-low gene cluster ii. Luminal gene cluster iii. Basal 
gene cluster iv. Proliferation gene cluster v. Lactating gene cluster. 
 
 
19 
 
 
Figure 3:  Murine intrinsic tumor dendrogram by sample. 
Clustering location of all murine tumors from Figure 2B. 
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Figure 4: Murine intrinsic tumor dendrogram by mouse model. 
Clustering location of all tumors from Figure 2B as displayed by their mouse model. 
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Other models showed a ‘semi-homogeneous’ gene expression pattern, defined as ≥ 
80% of tumors from a single GEMM being found within two classes. These included Pik3ca- 
H1047R, TgMMTV-Atx, TgMMTV-Fgf3, TgMMTV-Hras, TgWap-T121, and TgMMTV-
Wnt1. Interestingly while maintaining the TgMMTV-Wnt1 mouse colony, it was observed 
that there might be two types of tumors based on latency, namely early and late arising 
tumors. This observation was also reflected in the two TgMMTV-Wnt1 expression classes 
that also differed by median tumor latency: Wnt1-Early
Ex
 (8.8 weeks) and Wnt1-Late
Ex
 (22.2 
weeks) (Wilcoxon Rank Sum p-value < 0.001). Lastly, about 40% of MMTV provirus driven 
Wnt1 tumors have cooperative activation of FGF signaling [38], a phenotype that is known 
to decrease tumor latency [16], and consistent with this, 88% (7/8) of TgMMTV-Wnt1/iFgfr2 
tumors in our dataset were also classified as Wnt1-Early
Ex
. 
The remaining models had ‘heterogeneous’ gene expression patterns, which were 
defined as no two classes containing at least 80% of the tumors analyzed: Brg1
+/-
 (five 
classes), DMBA-induced (five), p18
-/-
 (three), Rb1
-/-
 (five), TgMMTV-Aib1 (four), 
TgMMTV-Cre Brca
Co/Co
 Trp53
+/-
 (three), TgMMTV-Lpa (four), Trp53
-/-
 (seven), and  
Trp53
+/-
 irradiated (four). Similar to recent reports [32], the Trp53
-/-
 model (which is distinct 
from the Trp53
+/-
 irradiated model) was primarily defined by three murine classes in this 
analysis: p53null-luminal
Ex
 (27/58), p53null-basal
Ex
 (15/58), and Claudin-low
Ex
 (7/58). 
To begin investigating the defining features of these classes, a comparison of selected 
cell lineage markers was performed (Figure 2C). Several mouse classes highly expressed 
luminal cell markers (e.g. Erbb2, Esr1, Krt18, and/or Krt19), including Erbb2-like
Ex
, 
PyMT
Ex
, Neu
Ex
, Myc
Ex
, and Stat1
Ex
. Other classes expressed basal cell cytokeratins (e.g. 
Krt5, Krt14 and/or Krt17) including Wnt1-Late
Ex
, Wnt1-Early
Ex
, p53null-Basal
Ex
,   
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 Figure 5: Murine intrinsic cluster signatures according to tumor subtype 
Standardized, average expression values for the dominant individual gene clusters from 
Figure 2i-v are shown according to the murine classes (left panels) and the human subtypes 
(right panels) using the human UNC308 human breast cancer dataset. A. Murine claudin-low 
subtype defining gene set. B. Murine luminal subtype gene set. C. Murine basal-like subtype 
gene set. D. Murine proliferation-associated gene set. E. Murine lactation associated gene 
set.  
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Squamous-like
Ex
, Class14
Ex
, and C3Tag
Ex
. As identified previously [31], a murine Claudin-
low
Ex
 class was observed to be characterized by low expression of multiple cell adhesion 
genes (Cldn3, Cldn4, and Cldn7) and high expression of epithelial-to-mesenchymal transition 
(EMT) genes (Snai1 and Zeb2), similar to the human claudin-low subtype [34]. 
 
Comparison of murine class defining gene sets versus human tumor subtypes 
To specifically compare murine classes to human breast cancer subtype features, each 
murine class defining signature (Figure 2i-v) was tested for differential expression across the 
human subtypes using the UNC308 dataset (Figure 5A-E) [34]. For example, the high 
expression signature that defines the murine Claudin-low
Ex
 class (Figure 2i, including Hic1, 
Il6st, Klf2, Maf, Pdgfra, Prrx1, Snai1) was also the most highly expressed in human claudin-
low tumors (Figure 5A).  
Figure 2ii shows genes that are highly expressed in the newly identified Stat1
Ex
 and 
Class14
Ex
 murine classes, which show luminal characteristics (e.g. Foxa1, Esrrb) and are the 
most highly expressed in human luminal A tumors (Figure 5B). While most of the GEMMs 
in this dataset are considered estrogen receptor (ER) negative, murine models comprising 
these two classes (Stat1
-/-
 and Pik3ca-H1047R, respectively) were often ERα+ [9, 11], and 
these data suggest that they overall have a ‘luminal’ expression profile. Interestingly, these 
classes cluster independent from the previously defined murine luminal models, TgMMTV-
Neu and TgMMTV-PyMT. Consistent with the individual cell lineage marker analysis, the 
Wnt1-Late
Ex
, Wnt1-Early
Ex
, p53null-Basal
Ex
, Squamous-like
Ex
, and Class14
Ex
 murine classes 
express a basal-like gene signature (Figure 2iii). As in human tumors, a proliferation 
signature (Figure 2iv) further distinguishes these murine classes, with highest expression in   
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Table 2: Gene set analysis of murine classes 
Displayed are the p-values for the gene set analysis comparison of each murine class versus 
each murine class described in Herschkowitz et al 2007. Empty boxes are trending 
associations, while filled boxes are significant associations (p<0.05, FDR<0.1). 
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murine C3Tag
Ex
 and human basal-like tumors, and lowest expression in normal tissues from 
both species. This finding is likely due to the loss of RB1 function in both human basal-like 
[39, 40] and TgC3(1)-Tag murine tumors (due to T-antigen expression). Lastly, Figure 2v 
highlights a gene cluster that is highly expressed in several murine classes including Erbb2-
like
Ex
, PyMT
Ex
, and Neu
Ex
; this signature was lower in normal mammary tissue, but highly 
expressed in the two lactating mammary samples (Figure 5E). Consistent with this 
observation, many of the genes in this signature are involved in alveolar function (e.g. Abcg2, 
Folr1, and Lalba). 
 For the dual purpose of validating our new classification system and for investigating 
the degree of diversity in our expanded dataset, the murine classes defined here were 
compared to those from Herschkowitz et al 2007 [31] using gene set analysis (GSA) (Table 
2). The majority of the Herschkowitz et al 2007 classes had one-to-one matching 
counterparts to those described here; however, two previous groups (IX-WapTag and X-
C3Tag) were combined into a single class in our dataset (C3Tag
Ex
). Importantly, several of 
the 17 murine classes defined here were not present within the ten classes of Herschkowitz et 
al 2007 (Erbb2-like
Ex
, Class3
Ex
, Class8
Ex
, and Stat1
Ex
), almost all of which were populated 
by GEMMs that were new to this study. 
 Given the discovery of novel murine classes, it was of great interest to determine the 
degree to which this expanded murine dataset might better encompass the molecular diversity 
of the human subtypes. To directly compare tumors across species, this mouse and the 
previously published UNC308 human datasets were normalized into a single expression 
dataset and hierarchical clustered using a combined mouse and human [41] intrinsic gene list 
(Figure 6). While technical differences between the two datasets (e.g. different microarray   
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Figure 6: Human and murine intrinsic co-cluster 
A. Supervised cluster using a combined human and mouse intrinsic gene list and all murine 
and UNC308 human arrays. Broad tumor clusters are highlighted with names corresponding 
to the major human subtype(s) found within each. B. Clustering location of all tumors as 
displayed by their human subtype or mouse class. C. Basal gene cluster. D. Proliferation 
gene cluster. E. Normal breast gene cluster F. Claudin-low subtype high expression gene 
cluster G. Luminal gene cluster. 
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Table 3: Gene set analysis of murine classes and human subtypes 
Displayed are the p-values for the gene set analysis comparison of each murine class versus 
each human subtype. Empty boxes are trending associations, while filled boxes are 
significant associations (p<0.05, FDR<0.1). 
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platforms, different common references) may limit interspecies clustering, several across 
species dendrogram nodes were observed (Figure 6A). Interestingly, all major nodes 
contained a combination of human and mouse subtypes (Figure 6B), indicating a degree of 
similarity not only between specific corresponding tumor subtypes, but also globally across 
species. Most of the major intrinsic gene sets driving the nodes are highlighted below the 
dendrogram, including the basal (2.4C), proliferation (2.4D), normal breast (2.4E), claudin-
low subtype high expression (2.4F), and luminal (2.4G) signatures. These clusters highlight 
the broad conserved intrinsic features between mouse and human tumors. For instance, most 
C3Tag
Ex 
tumors cluster with the basal-like subtype, an association that is driven in part by the 
high expression of the proliferation gene set [31], which is known to contain many E2F-
regulated genes. 
 To more objectively validate the trans-species associations observed in Figure 6, 
similarity between specific human and mouse subtypes was measured GSA (Table 3) [42]. 
Using this approach, a murine class was judged to be a strong human subtype counterpart if 
the human-to-mouse comparison was statistically significant (p ≤ 0.05) in at least two of the 
three human datasets analyzed (UNC308 [34], Combined855 [43], and TCGA547 [39]). 
As previously observed [31], the murine Normal-like
Ex
, C3Tag
Ex
, and Claudin-low
Ex
 
classes associate with the human normal-like, basal-like, and claudin-low subtypes, 
respectively. The new murine class, Erbb2-like
Ex
, was associated with the human HER2-
enriched subtype across all three human data sets; this human breast cancer subtype did not 
associate with any previously characterized murine class [31], indicating an increased ability 
for the current dataset to encompass more of the major human intrinsic subtypes. With this 
larger sample size, a link was also identified between the Myc
Ex
 class and human basal-like 
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breast cancer, which is consistent with multiple human studies linking basal-like breast 
cancers with cMYC amplification and expression signatures [39, 44]. Interestingly, a 
connection between the Myc
Ex
 class and human luminal B tumors was also identified, 
highlighting Myc activation as a potentially important etiological mechanism that is shared 
between these two aggressive human subtypes. 
Previously defined as a ‘luminal’ model [31], the NeuEx murine class associated with 
the human luminal A subtype in this newest analysis; this correlation was somewhat 
surprising given the lack of ERα and ERα-regulated gene expression in the murine NeuEx 
class, but does suggest that human Luminal A tumors have many ERα independent features. 
Although the murine p53null-Basal
Ex
 versus human comparisons were not significant after 
controlling for multiple comparisons, an almost consistent significant association was seen 
with human basal-like tumors (p=0.04, 0.05, and 0.06) in all three human datasets. Lastly, 
Class14
Ex
 tumors were identified as a counterpart for normal-like human tumors, and of the 
13 murine tumors comprising this class, 38% (5/13) are from the Pik3ca-H1047R model. 
This class clusters independent of normal mammary tissue samples (which are all classified 
as Normal-like
Ex
), indicating that this association is possibly not driven by contamination of 
normal tissue in the tumor biopsies. 
 
Conserved tumorigenic pathway signatures identified between human-mouse 
counterparts 
Many researchers have hypothesized that gene expression signatures may be a more 
robust means of utilizing gene expression data for discovery and pathway-based 
classification as they are composed of tens to hundreds of coordinately expressed genes. To 
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take advantage of this approach, the median expression values for 963 publicly available 
pathway gene-signatures were calculated separately for the mouse and human datasets, and a 
two-class (Class X versus all others) Significance Analysis of Microarrays (SAM) was used 
to identify pathways that were highly expressed by each class/subtype with a false discovery 
rate (FDR) of 0%. To visualize pathway similarities across species, gene signatures highly 
expressed within each mouse class were first grouped into ‘pathway meta-signatures’, similar 
to the way coordinately expressed genes can be grouped into ‘gene signatures’. The average 
value of these ‘pathway meta-signatures’ was then calculated for each human tumor and 
displayed as standardized boxplots based on their human breast cancer subtype for the eight 
mouse classes with human counterparts (Figure 7). These boxplots allow for broad trends to 
be observed between the pathways highly expressed within each mouse class relative to 
human tumors, and in all instances, identified tens of pathway signatures that were 
commonly expressed across species. For instance, the average expression of the 135 pathway 
signatures highly expressed in C3-Tag
Ex
 tumors were also very highly expressed in human 
basal-like tumors (Figure 7, top left panel), consistent with the gene level analysis. While 
these trends are informative, it was of most importance to identify the specific pathways that 
were highly expressed in both mouse and their human counterparts; it is likely that these 
shared pathways provide etiological insight and highlight potentially important cancer 
driving pathways. A subset of the pathways identified as highly expressed in both human and 
mouse counterparts are displayed below each graph. 
Three murine classes overlapped with human basal-like tumors (Figure 7). One 
common feature between these human and mouse tumors included Trp53 loss/mutation, 
which in human basal-like tumors occurs in >85% of the samples [39]. This trait was most  
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Figure 7: Conserved signaling pathways between human-mouse counterparts 
A two-class SAM (Class X versus all others) was used to identify pathways highly expressed 
in each murine class. Pathways highly expressed with a FDR of 0% were grouped together to 
define a ‘pathway meta-signature’ for each murine class (with the total number of pathway 
signatures included shown on the left axis). The standardized, average expression values of 
each ‘pathway meta-signature’ were calculated in the UNC308, Combined855, and 
TCGA547 human datasets, which are displayed as boxplots according to their intrinsic 
human subtype. A subset of the pathways independently identified to be highly expressed in 
both human-mouse counterparts (as indicated by the ‘*’) for all three human datasets is 
displayed below each plot. 
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apparent in C3-Tag
Ex
 and p53null-Basal
Ex
 murine tumors on both a genetic and expression 
level. The second cardinal feature of human basal-like tumors is high proliferation, primarily 
resulting from RB loss [39, 40]. Consistent with this finding, all three basal-like mouse 
classes highly expressed cell cycle and/or RB-pathway related signatures. In addition, 
C3Tag
Ex
 tumors were enriched for KRAS amplicon genes, b-MYB activation, mutant 
PIK3CA, and FAS signaling. Murine Myc
Ex
 tumors were also enriched for b-MYB activation 
and mutant PIK3CA signaling, in addition to a HER1-pathway signature and E2F signaling. 
Lastly, the p53null-Basal
Ex
 class was enriched for a SRC activation signature, a HER1-
pathway signature, and the KRAS amplicon. These findings are relevant since it has been 
shown that human basal-like tumors also highly express the b-MYB signature [45], are often 
KRAS [46] and cMYC amplified [39], and show a PIK3CA-activation signature [39, 47]. 
Thus for human and murine basal-like cancers, both the underlying molecular genetics and 
their expression profiles are very similar across species. 
Human and mouse claudin-low tumors also share many features, including high 
expression of immune cell associated genes/signatures (e.g. BCR, PD1, and TCR signaling), 
which is likely due to consistently infiltrating immune cells. Both human HER2-enriched and 
murine Erbb2-like
Ex
 tumors highly expressed the EIF2 pathway, GATA3 induced genes, and 
p53 independent DNA damage response genes. Human Luminal A and murine Neu
Ex
 tumors 
exhibited high expression levels of several tyrosine kinase associated pathway signatures 
including EGF, HER2, PDGF, TGFα, and PIK3CA signaling. In support of this EGF/HER2 
pathway finding, it was recently shown that TgMMTV-Neu tumors therapeutically respond 
to lapatinib (a dual EGFR and HER2 inhibitor) treatment [48], as would be predicted by the 
nature of this transgene. In addition to mimicking human basal-like tumors, the murine 
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Myc
Ex
 class was also a counterpart for the luminal B subtype. Interestingly, many of the 
same pathways that were common with basal-like tumors are also shared with luminal B 
tumors, highlighting potentially important etiological events that are shared between these 
two aggressive intrinsic subtypes; these features include proliferation/RB related pathways, 
increased chromosome instability, and altered DNA damage repair mechanisms. 
 
DISCUSSION 
 Human breast cancer is a genetically complex disease consisting of well characterized 
molecular subtypes [33, 35]. Mouse models can provide an excellent resource to study 
human disease, but it is essential to ensure the chosen models accurately replicate genetic 
alterations and overall phenotypes observed in human tumors. Thus, a number of 
considerations must be kept in mind when designing and/or selecting GEMMs to mimic the 
human disease state; these features should include intramodel tumor diversity, the degree of 
genetic similarity, the degree of transcriptomic similarity, and histological similarity (a topic 
not addressed here). By consolidating mouse models of breast carcinoma into a single 
dataset, this study was able to investigate the first three of these issues, in which we 
identified murine models for all of the major human expression subtypes. 
 To address intramodel tumor diversity, three types of models were identified based on 
hierarchical clustering analysis: ‘homogenous’, ‘semi-homogeneous’, and ‘heterogeneous’. 
‘Homogeneous’ GEMMs were associated with a single murine expression class and were 
generally created through the expression of oncogenes, possibly relying less on secondary or 
tertiary mutations that arise during tumor progression. These GEMMs make good 
experimental models because the phenotypes of individual tumors are consistent and similar. 
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‘Semi-homogeneous’ models, such as TgMMTV-Wnt1, were associated with two murine 
classes. We hypothesize that unknown secondary events after the initial transgene lesion 
determine the class fate of these developing tumors. These varying combinations of 
secondary lesions may cooperate with aberrant Wnt1 signaling to target different mammary 
cell populations, contributing to model complexity. The last type of model comprises tumors 
with ‘heterogeneous’ gene expression patterns (i.e. models showing three or more distinct 
phenotypes). In contrast to ‘homogeneous’ models, the majority of the ‘heterogeneous’ 
models were based on disrupting the function of tumor suppressor genes. Again, we 
hypothesize that secondary events after the initial transgene lesion are involved in the class 
fate determination of these tumors. For example, the Trp53
-/-
 model shows specific DNA 
copy number changes associated with each expression class [32]. From an experimental 
perspective, special considerations (i.e. phenotyping each individual tumor) must be made to 
account for this heterogeneity, especially when these models will be utilized for therapeutic 
efficacy testing. 
 Despite the diversity of the models tested here, we found that these mouse models 
collapse into distinct murine classes which recapitulate specific human subtypes on a gene 
expression-based level. These results are important as they allow for the identification of 
shared characteristics/lesions between murine and human tumors, and they direct researchers 
toward appropriate in vivo models of specific human subtypes for future experimental 
testing. Basal-like breast tumors are one the most aggressive subtypes of breast cancer. 
Herein, we find that three murine classes recapitulated human basal-like breast cancers: 
C3Tag
Ex
, Myc
Ex
, and p53null-Basal
Ex
. The human basal-like subtype is characterized by high 
proliferation [49], genomic instability [46], and expression of a c-MYC signature [39, 44]. 
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These murine classes share these hallmarks as evident by high expression of the proliferation 
gene cluster, cell cycle pathways, and chromosome instability gene-signatures; thus there are 
clear GEMMs of human basal-like tumors that share both common genetic drivers and 
expression features. 
Murine Claudin-low
Ex
 tumors were identified that significantly mimic the human 
claudin-low subtype; however, no homogeneous murine model was specific to this 
class/subtype. Instead, rare tumors from multiple heterogeneous models coalesced into the 
murine claudin-low group. As an experimental solution to this heterogeneous GEMM 
complication, the T11 orthotopic, transplantable syngeneic model was derived from a 
Claudin-low
Ex
 BALB/c Trp53
-/-
 tumor (753R), which maintains its claudin-low expression 
features even after multiple transplant passages [32].  This transplantable model has been 
used for extensive therapeutic testing [48], thus suggesting that one method of ‘capturing’ a 
heterogeneous model in a single state can be accomplished via the serial transplantation of a 
phenotypically characterized individual tumor. As in the human claudin-low subtype, Trp53 
mutation/loss was a common genetic event in mouse Claudin-low
Ex
 tumors. Similarly, both 
species highly express EMT related genes, inflammatory gene-signatures, and have low 
expression of many epithelial cell adhesion genes including E-cadherin [34]. 
 Discovered here was the Erbb2-like
Ex
 murine class, which associated with human 
HER2-enriched tumors even without highly expressing the Erbb2 gene; no mouse model 
from our previous studies mimicked this aggressive human tumor subtype. One 
homogeneous model was found within this class, namely WapCre-Etv6. This model 
expresses the Etv6-Ntrk3 fusion gene product, a protein that has been associated with 
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secretory breast cancers [50]. Consistent with this, we observed that murine Erbb2-like
Ex
 
tumors highly express a gene signature in common with lactating normal mammary tissue. 
For the human luminal breast cancer subtypes, our previous study identified that the 
TgMMTV-Neu model represents the luminal subtypes more than it resembles HER2-
enriched tumors [31]. We provide further evidence here that the murine Neu
Ex
 class 
specifically associates with human luminal A tumors. Conserved with humans, murine Neu
Ex
 
tumors highly express several tyrosine kinase pathway related gene-signatures, namely 
EGFR and HER2, which would be expected based upon the nature of the Neu/ERBB2 
transgene. It has been shown that TgMMTV-Neu tumors regress with lapatinib treatment 
[48], giving credence to our approach for identifying drug targetable driver/maintenance 
pathways in these tumors using a computational pathway-based approach. Interestingly, only 
the murine Myc
Ex
 class was shown to consistently associate with luminal B tumors. Since the 
Myc
Ex
 class was also identified as a basal-like model, aberrant Myc activation may be a 
common hallmark of these two aggressive subtypes. 
While our main focus was to identify human-to-mouse disease counterparts, about 
half of the mouse classes did not statistically associate with specific human subtypes by our 
broad analysis. Several of these mouse specific classes, however, had clear basal-like tumor 
expression features including WapINT3
Ex
, Wnt1-Late
Ex
, Wnt1-Early
Ex
, and Squamous-like
Ex
. 
Unlike the other three, the Squamous-like
Ex
 class consisted of a variety models (e.g. Pik3ca-
H1047R, Brg1
+/-
, and DMBA-induced) and trended toward an association with human 
claudin-low tumors. Similarly, several classes had luminal expression features, highlighted 
by PyMT
Ex
 and Stat1
Ex
. Although the PyMT
Ex
 class had a relatively small number of 
samples, these tumors trended toward an association with the luminal B subtype. The Stat1
Ex
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class also had several strong luminal features, consistent with prior characterization of this 
model [11]. Given the expression of ERα in these STAT1-defecient tumors [11], the lack of 
an association with either the luminal A or luminal B human subtypes was unexpected. 
An unanswered question concerning these human-to-mouse associations is the 
finding that murine classes like Erbb2-like
Ex
, and Neu
Ex
, associate with specific human 
subtypes despite the fact that they apparently do not show expression of one of these human 
subtype defining genes (HER2/ERBB2 in the case of Erbb2-like
Ex
 and ESR1 in the case of 
Neu
Ex
). Three hypotheses that could explain this finding are: 1) the cell type of origin of the 
tumor (but not a genetic driver) is the same across species and this is the major linking 
phenotype, 2) additional unknown genetic driver(s) are responsible for the common 
phenotype across species, or 3) some combination of hypothesis 1 and 2. We favor the 
common cell type of origin hypothesis, but additional experiments like lineage tracing will be 
required to unequivocally determine this.  
Related to this, there are at least two confounding features within our dataset that 
should also be considered when interpreting these results. First, most of the oncogene-driven 
mouse models analyzed here used either the MMTV or WAP promoter in their design. If the 
activity of these promoters varies as a function of specific mammary cell types, such as 
luminal versus myoepithelial cells, then only those cells that naturally use these promoters 
would ever give rise to a tumor in these models; we note that most of the MMTV or WAP 
driven tumors were luminal. Second, similar complications potentially exist with regards to 
mouse strain. Varying the background genetics in which a model is designed can influence 
tumor phenotype, and thus classification. Unfortunately, our dataset is underpowered to 
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adequately address these two confounding features, but future experiments/models could be 
designed to address these questions. 
While some of the mouse classes were identified as good counterparts for specific 
human subtypes, many were not. There are several possibilities to explain this lack of 
association. The first is that these classes are specific to murine mammary carcinomas and do 
not have a matching counterpart in humans. The second might be that these murine classes 
model rare phenotypes that exist in only a small subset of human breast cancer patients, and 
that these rare human subtypes were not present in the datasets used here. Similarly, more 
mouse tumors for classes with small numbers may be required to increase statistical power to 
detect an association; for example, we hypothesize this to be the case for the PyMT
Ex
 class. 
The third possibility is that these novel murine classes share phenotypes with multiple human 
subtypes, and thus may never be classified as being similar to a single human subtype. Some 
murine tumor features were shared across multiple human subtypes (e.g. Myc
Ex
 with human 
basal-like and luminal B), which our presented analysis is more 
 likely to undervalue. 
While this study provides a framework for identifying GEMMs that could be useful 
for preclinical drug testing, the simultaneous analysis of 27 mouse models restricted our 
trans-species comparisons to only expression based analyses. The scope of our future work 
will focus on using models selected based upon these data for preclinical therapeutic testing 
to better determine the translational utility of these GEMMs. These experiments are already 
underway and producing promising results using the TgMMTV-Neu, TgC3(1)-Tag, and the 
claudin-low T11 models [48, 51-53]. For example in Roberts et al. [51], we showed that the 
CyclinD1 dependent TgMMTV-Neu tumors are sensitive to a CDK4/6 inhibitor, while the 
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basal-like TgC3(1)-Tag tumor were not; these studies are consistent with findings coming 
from human clinical trials of luminal/ER+ breast cancers, which were generally noted to be 
sensitive to a CDK4/6 inhibitor [54]. Similarly, a trans-species genetic screen by Bennett et 
al. [53] identified two ribonucleotide reductase genes (RRM1 and RRM2) and a checkpoint 
kinase (CHK1) as potential targets for triple-negative breast cancer patients, which they 
validated in both species with drug treatment experiments using TgC3(1)-Tag and human 
xenograft tumors. 
 
CONCLUSION 
In summary, we consolidate 27 murine models of breast carcinoma into the largest 
comprehensive genomic dataset to date, and we provide a detailed characterization of each to 
better understand how these GEMMs recapitulate phenotypes of the human subtypes. The 
data presented here provide insight into the molecular pathways involved in specific breast 
cancer subtypes and should serve as a useful resource when designing preclinical studies and 
interpreting their results. 
 
MATERIALS AND METHODS 
Gene expression microarrays 
A murine tumor dataset of 385 deoxyribonucleic acid (DNA) gene expression 
microarrays from 27 GEMMs of mammary carcinoma was compiled (Table 1A). 275 of 
these samples were obtained from multiple previous publications (Gene Expression Omnibus 
accession numbers: GSE3165, GSE8516, GSE9343, GSE14457, GSE15263, GSE17916, and 
GSE27101). The other 110 microarray samples (GSE42640) represent newly obtained tumor 
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samples from multiple participating investigators using methods approved by international 
animal husbandry guidelines. Total ribonucleic acid (RNA) was purified from 20-30mg of 
mouse mammary tumor using Qiagen's RNeasy Mini Kit following manufacture protocols. 
RNA quantity and quality were determined using the Nanodrop spectrophotometer and 
Agilent Bioanalyzer, respectively. Total RNA was reverse transcribed and labeled with 
cyanine-5 (Cy5) dye for experimental samples and cyanine-3 (Cy3) dye for mouse reference 
samples [31] using the Agilent Low RNA Input Fluorescent Linear Amplification Kit. Equal 
quantities of labeled mouse reference RNA and tumor RNA were co-hybridized overnight to 
Agilent microarrays, washed, scanned and signal intensities were determined. 
 All tumor samples were co-hybridized to one of three Agilent Technology gene 
expression microarray types: 22K, 4X44K, or 4X180K (Figure 1). Two ‘homogeneous 
expression’ murine models [31], namely TgMMTV-Neu and TgC3(I)-Tag, were analyzed on 
all three array types. Therefore, we used both of these models to normalize expression 
between microarray types [32]. Ten microarrays (five TgMMTV-Neu and five TgC3(I)-Tag) 
from each array type were used for normalization (30 microarrays total).  All microarray data 
was independently extracted from the UNC Microarray Database for each array type as log2 
Cy5/Cy3 ratios, filtering for probes with Lowess normalized intensity values greater than ten 
in both channels and for probes with data on greater than 70% of the microarrays [31, 34]. 
Before normalization, each data set was imputed (via the ten-nearest neighbor gene values) 
and then reduced to the probes that were present on all three array type datasets (11690 
probes, 11167 genes). Using the ten normalization arrays per three array platforms, the 
median expression value was calculated for each probe, on each array type, and a 
normalization factor was applied independently to each probe so the median was the same for 
41 
 
each array type. Probe expression values were ‘median centered’ to obtain the final 
normalized dataset. A principle component analysis (PCA) was performed to verify the 
normalization. 
 
Murine intrinsic genes and subtypes 
 After removing technical replicates, the dataset was filtered to probes with at least 
three observations with an absolute log2 expression value greater than three using Gene 
Cluster 3.0 [56], which included 908 probes (899 genes). Hierarchical clustering was 
performed with this unsupervised probe list using centroid linkage and was viewed with Java 
Treeview v1.1.5r2 [57]. Potential ‘intrinsic groups’ of murine samples were defined as any 
set of samples/arrays within this hierarchical cluster that had a Pearson correlation value of 
0.65 or greater [31]. Using these defined groups (42 total), an ‘intrinsic gene list’ of 1855 
probes (1841 genes) was identified with Intrinsic Gene Identifier v1.0 (Max Diehn/Stanford 
University) by using a cutoff of one standard deviation below the mean intrinsic gene value 
[31]. 
 To identify significant murine ‘intrinsic subtypes’, the 385 sample dataset was 
clustered again using the 1855 intrinsic probe list and SigClust [37] was used to identify 
groups of samples with a significant association to one another (p<0.01) [32]. GEMM classes 
were defined as having at least five tumors and a SigClust p-value ≤ 0.01, yielding 17 
classes. Class specific probes/genes were determined using a two class (class X versus all 
other samples) SAM analysis (v3.11) [34, 58]. 
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Human and mouse intrinsic gene cocluster 
 Prior to combining the two datasets, probes corresponding to orthologous gene IDs 
(as determined by the Mouse Genome Informatics of the Jackson Laboratory) were averaged 
for both the mouse and UNC308 human datasets. Using only orthologous genes found in 
both datasets (8034 genes), each tumor and gene was standardized to have an average 
expression of zero and a standard deviation of one (N(0,1)) separately for each species. Then, 
the datasets were merged and each gene was median centered to obtain the final, normalized 
combined dataset. A merged intrinsic gene list was created by combining the 1841 mouse 
intrinsic genes defined here and the 1918 human intrinsic genes from Parker et al [41] (3310 
unique genes in the combined gene set). An intrinsic gene set hierarchical co-cluster was 
performed using centroid linkage in Gene Cluster 3.0. 
 
Comparison of murine and human expression subtypes 
 To identify possible commonalities between mouse classes and the human intrinsic 
subtypes of breast cancer [34, 41], we used the gene set analysis (GSA) R package v1.03 [42] 
and R v2.12.2. Human subtype specific gene lists were derived for each subtype with a two 
class (subtype X versus all other samples) SAM analysis independently for all of the unique 
primary tumor samples from Prat et al 2010 (referred to as the UNC308 dataset) [34], from 
Harrell et al 2011 (Combined855 dataset) [43], and from TCGA 2012 (TCGA547 dataset) 
[39]. Human subtype-specific genes were classified as being highly expressed in the subtype 
of interest and having a SAM FDR of 0%. Murine classes were then analyzed for significant 
overlap with each dataset’s human subtype-specific gene sets using GSA. Significant overlap 
was defined as having p ≤ 0.05 and FDR ≤ 0.1 to control for multiple comparisons [42]. 
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These same methods were used to identify significant overlap between our 17 newly derived 
murine classes and the 10 previously defined GEMM classes from Herschkowitz et al 2007 
[31], noting that all 122 arrays used for the Herschkowitz et al study were also present within 
the 385 sample dataset used here. 
 
Conserved pathway gene signatures 
 Only genes that were found in both the human and murine datasets were considered 
for gene-signature analysis in order to eliminate the influence of genes found in only one 
dataset. Prior to calculating gene-signature values, the human and murine datasets were 
separately collapsed by averaging rows corresponding to the same gene symbol. Median 
expression values were calculated for 963 publically available pathway-based gene 
signatures using methods described in Fan et al 2011 [59, 60]. A two class SAM (class or 
subtype X versus all other samples) was used to identify pathway-signatures enriched in 
murine and human classes/subtypes, which were defined as being upregulated with a FDR of 
0%. 
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CHAPTER 3: LUMINAL PROGENITOR AND FETAL MAMMARY STEM CELL 
EXPRESSION FEATURES PREDICT BREAST TUMOR RESPONSE TO 
NEOADJUVANT CHEMOTHERAPY
1
 
 
OVERVIEW 
Background 
Mammary gland morphology and physiology are supported by an underlying cellular 
differentiation hierarchy. Molecular features associated with particular cell types along this 
hierarchy may contribute to the biological and clinical heterogeneity observed in human 
breast carcinomas. Investigating the normal cellular developmental phenotypes in breast 
tumors may provide new prognostic paradigms, identify new targetable pathways, and 
explain breast cancer subtype etiology. 
 
Methods 
We used transcriptomic profiles coming from fluorescence-activated cell sorted 
(FACS) normal mammary epithelial cell types from several independent human and murine 
studies. Using a meta-analysis approach, we derived consensus gene signatures for both 
species and used these to relate tumors to normal mammary epithelial cell phenotypes. We 
then compiled a dataset of breast cancer patients treated with neoadjuvant anthracycline and 
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taxane chemotherapy regimens to determine if normal cellular traits predict the likelihood of 
a pathological complete response (pCR) in a multivariate logistic regression analysis with 
clinical markers and genomic features such as cell proliferation. 
 
Results 
Most human and murine tumor subtypes shared some, but not all, features with a 
specific FACS purified normal cell type; thus for most tumors a potential distinct cell type of 
‘origin’ could be assigned. We found that both human luminal progenitor and mouse fetal 
mammary stem cell features predicted pCR sensitivity across all breast cancer patients even 
after controlling for intrinsic subtype, proliferation, and clinical variables. 
 
Conclusions 
This work identifies new clinically relevant gene signatures and highlights the value 
of a developmental biology perspective for uncovering relationships between tumor subtypes 
and their potential normal cellular counterparts. 
 
BACKGROUND 
The mammalian breast is a dynamic organ, with major morphological changes 
occurring during organogenesis, puberty, pregnancy, lactation and involution [1]. Underlying 
these mammary gland changes is a complex cell hierarchy that supports these processes [2-
4]. The simplest model places the multi-potent mammary stem cell (MaSC) at the base of this 
hierarchy, having extensive, self-regenerative potential [5]. During mammary development, 
the MaSC has been proposed to divide asymmetrically to produce basal/myoepithelial cells 
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as well as luminal progenitors (LumProg), which have more restricted proliferative and 
differentiation capabilities [5]. LumProg cells are capable of further differentiation into 
mature luminal (MatureLum) cells, such as Estrogen Receptor (ER)-positive ductal 
epithelium, which have an even more limited proliferative potential and some of which are 
terminally differentiated [5]. 
Breast tumors may originate from several, if not all, of the cell types within this 
complex mammary hierarchy. These various cellular foundations for tumor initiation may 
help explain the heterogeneous nature of human breast tumors [6], which consist of multiple 
histological and genomic subtypes; these genomic groups, which are defined by their gene 
expression profiles, have become known as the intrinsic subtypes of breast cancer and are 
referred to as basal-like, claudin-low, HER2-enriched, luminal A, and luminal B [7-10]. A 
simple etiological explanation for these different subtypes involves a one-to-one relationship 
between each intrinsic subtype and a distinct cell-type-of-origin that largely maintains its 
phenotypic identity after oncogenic transformation; however, both normal and neoplastic 
non-stem cells can acquire stem-like properties, suggesting that the normal cell hierarchy 
model could also include an element of reversibility [11]. This also raises the possibility that 
molecular features defining tumor subtypes, may be acquired during tumorigenesis [12]. 
Genetically engineered mouse models (GEMMs) of breast carcinoma develop 
heterogeneous tumors [13, 14], but the extent to which they represent human disease is an 
area of active investigation. We previously showed that murine mammary tumors comprise 
at least 17 distinct intrinsic subtypes/classes, with eight classes being identified as strong 
human subtype counterparts by gene expression similarity [14]. As with human breast 
cancer, the degree to which murine models reflect normal mammary epithelial 
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subpopulations requires further analysis. Characterization of the cellular features of these 
murine classes is also needed to better determine their preclinical utility, to shed light on 
trans-species associations [14], and to help interpret preclinical study observations [15-18]. 
 Several studies have independently profiled fluorescence-activated cell sorted 
(FACS) purified normal mammary cell types from both human [19-21] and murine [22, 23] 
mammary tissues. Here, we use a meta-analysis approach to compare the transcriptomic 
profiles from FACS-enriched mammary cell populations to each other and to primary 
tumors. These data not only identify a number of clinically relevant biomarkers that may be 
useful for predicting chemotherapy benefit, but also suggest a cell type of origin for many 
tumor subtypes. 
 
RESULTS 
Comparison of human mammary subpopulation transcriptomic datasets 
  Several groups have independently obtained transcriptomic profiles of normal human 
breast cells and compared the genomic biology of these different cell types with human 
tumors [19-21]. In these studies, normal mammary tissues obtained from female donors were 
FAC sorted using cell surface markers to enrich for specific mammary subpopulations before 
microarray analysis (Table 4 and Figure 8). While these initial studies were important, the 
datasets themselves were relatively small (n=12 for Lim et al. 2009, n=72 for Shehata et al. 
2012, n=18 for Prat et al. 2013), and few if any comparisons across studies were performed. 
Importantly, FACS-based cell fractionation can only enrich for specific subpopulations. 
Therefore, transcriptomic profiles reflect features of other contaminating cell types to varying 
degrees. As such, study specific biases may be present in any single dataset; therefore, we  
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 Table 4: Human FACS enriched normal mammary cell subpopulation studies 
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Figure 8: Flowchart of analysis 
Normal mammary tissue biopsies were taken from female patients (a) and FACS enriched 
into distinct mammary cell subpopulations (b). Transcriptome profiling was performed on 
each subpopulation using gene expression microarrays by three different studies (c). Within 
each study, genes highly expressed within each subpopulation were determined using a two-
class SAM (d). Genes commonly and specifically enriched within each subpopulation across 
studies were determined to identify ‘enriched’ gene signatures (e). Each ‘enriched’ signature 
was refined by supervised hierarchical clustering to identify gene ‘features’ highly correlated 
across a diverse set of human breast tumors (f). These gene signatures were then used for 
clinical testing (g). 
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Figure 9: Comparison of mammary subpopulations across studies 
a. Unsupervised hierarchical clustering was performed with the normal human mammary 
subpopulation dataset using any gene that had a log2 absolute expression value greater than 
three in at least four samples. b. Pearson correlations were determined between the average 
expression of each study’s subpopulations using all genes. c. The first three principle 
components were determined across the human mammary subpopulation dataset. 
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used consensus information from all three FACS-enriched human transcriptomic datasets to 
reduce technical and study-specific biases. 
Following DWD normalization [24], an unsupervised cluster of the most variably 
expressed genes was performed using Gene Cluster v3.0 by selecting all genes with an 
absolute log2 expression value greater than three in at least four samples (212 genes) (Figure 
9a). In general, the four major array dendrogram nodes correspond to the four FACS-
enriched mammary subpopulations, indicating that the most highly and variably expressed 
genes are similarly expressed across the different studies. Even when using all genes in the 
dataset, there is a high Pearson correlation within a given subpopulation across studies and 
low correlations to other subpopulations (Figure 9b). 
On a per-sample basis, the first principle component separated the stroma and adult 
mammary stem cell (aMaSC) samples from the luminal progenitor and mature luminal 
samples (Figure 9c). The second principle component separated the stroma and aMaSC 
samples into distinct groups, while the third principle component separated the luminal 
progenitor and mature luminal samples into distinct groups. The aMaSC subpopulation 
displayed the highest level of variation, which is likely attributable to varying degrees of 
contamination by other cell types. 
 
Human mammary cell subpopulation enriched gene signatures 
 As shown in Figure 9, there is a natural degree of variation between samples of a 
given subpopulation. We therefore developed gene signatures for each human mammary 
subpopulation by integrating consensus information across all three datasets (Table 4) to  
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Figure 10: Homo sapiens enriched gene signatures 
a. HsEnriched gene signatures were identified for each mammary subpopulation. First, the 
overlap of genes highly expressed within each subpopulation across studies was determined. 
This overlapping gene set was further filtered to remove genes also identified as enriched in 
another subpopulation to limit the signature to genes specific to an individual subpopulation. 
The remaining genes comprised the HsEnriched gene signature for that subpopulation, as 
indicated by the shaded box. b. The standardized average expression of the four HsEnriched 
gene signatures was calculated across three human datasets and displayed by intrinsic tumor 
subtype. c. A nearest centroid predictor using the HsEnriched gene signatures was used to 
determine which epithelial features each tumor most represented. To reduce spurious 
findings, any tumor with a negative silhouette width was considered to have a weak 
association and was labeled as ‘unclassified’. 
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identify the highest confidence subpopulation specific genes. First, genes highly expressed 
(FDR < 5%) within each mammary subpopulation were found using a two-class 
(subpopulation X versus all others) SAM analysis [25] within each dataset [19-21]. Second, 
the overlap of genes highly expressed within a particular subpopulation across studies was 
determined. Lastly, as it is possible in the above analysis to have the same gene in the 
signature of more than one subpopulation, genes that were identified to be significantly 
associated with more than one subpopulation were also removed. This resulted in a single, 
consensus Homo sapiens enriched (HsEnriched) signature per subpopulation (Figure 10a). 
The average Euclidean distance was determined using a 10-fold cross validation for each 
normal mammary subpopulation sample to centroids created using either the HsEnriched 
derived gene signatures or to centroids created using the gene signatures derived separately 
from each human study. The HsEnriched centroids had a significantly reduced Euclidean 
distance (~70%) to each mammary subpopulation (t-test p<0.0001), indicating greater 
specificity for the consensus HsEnriched signatures when compared to any individual 
dataset’s subpopulation signature. 
  We next evaluated the utility of these signatures for distinguishing human tumor 
subtypes. Figure 10b displays the standardized average expression of each HsEnriched 
signature across the human intrinsic breast tumor subtypes [7, 9] using over 3000 tumors [9, 
26, 27]. The aStr-HsEnriched signature was highest in claudin-low and normal-like tumors. 
Interestingly, claudin-low tumors also highly express the aMaSC-HsEnriched signature. High 
expression of the aMaSC-HsEnriched signature in claudin-low tumors is unlikely an artifact 
of stromal cells in these tumors since the Pearson correlation between the aStr-HsEnriched 
and aMaSC-HsEnriched signatures was -0.19 across the normal human mammary samples.  
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Table 5: Murine FACS enriched normal mammary cell subpopulation studies 
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The LumProg and MatureLum -HsEnriched signatures were most highly expressed in 
basal-like and luminal subtype tumors, respectively (Figure 10b). 
We noted a considerable degree of signature variation within a subtype, indicating 
that it is not necessarily the case that all tumors of a given subtype share features with the 
same normal cell type. A nearest centroid predictor with a 10-fold cross validation error rate 
of 4.8% was created to individually determine which normal mammary epithelial 
subpopulation is most similar to each tumor. Samples with positive silhouette widths [28] 
were considered to have a strong association to their particular subpopulation, with all other 
tumors being categorized as ‘unclassified’ [29] (Figure 10c). Specifically, 94% of basal-like 
tumors had LumProg expression profiles. The claudin-low subtype had the highest 
percentage of tumors classified as aMaSC (18%), although most claudin-low tumors were 
classified as having LumProg features (59%). The HER2-enriched subtype was 
predominantly classified as having LumProg expression features. The luminal A and B 
subtypes were most similar to the MatureLum subpopulation. 
 
Murine mammary cell subpopulation enriched gene signatures 
 Several groups have also profiled normal murine mammary cell type expression 
features using FACS [22, 23] (Table 5). In addition to highlighting conserved expression 
features across species [22], murine studies are uniquely positioned to enable comparisons 
with  developmental states not easily accessed in humans, including early fetal development 
[23]. We were particularly interested in fetal mammary stem cells (fMaSC) [23], which is a 
distinct cell population not captured in any human study performed thus far (Table 6). Using 
the same approach that we used to derive the HsEnriched signatures, we created Mus  
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Table 6: Gene set analysis of human and murine cell subpopulations 
A comparative analysis of each human subpopulation versus each murine subpopulation was 
performed using GSA. The FDR is displayed for all comparisons with a positive association. 
Statistically significant associations (FDR<0.05) are highlighted. 
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Figure 11: Mus musculus enriched gene signatures 
a. MmEnriched gene signatures were identified for each mammary subpopulation. First, the 
overlap of genes highly expressed within each subpopulation across studies was determined. 
This overlapping gene set was further filtered to remove genes also identified as enriched in 
another subpopulation to limit the signature to genes specific to an individual subpopulation. 
The remaining genes comprised the MmEnriched gene signature for that subpopulation, as 
indicated by the shaded box. b. The standardized average expression of the five MmEnriched 
gene signatures was calculated across a murine dataset and displayed by intrinsic tumor class. 
c. A nearest centroid predictor using the MmEnriched gene signatures was used to determine 
which epithelial features each tumor most represented. To reduce spurious findings, any 
tumor with a negative silhouette width was considered to have a weak association and was 
labeled as ‘unclassified’. 
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musculus enriched (MmEnriched) signatures for each murine mammary subpopulation 
(Figure 11a) [22, 23]. 
We calculated the standardized average expression of each MmEnriched signature 
across the murine intrinsic subtypes/classes (Figure 11b) [14]. As in human tumors, the Str-
MmEnriched signature was most highly expressed in Normal-like
Ex
 and Claudin-low
Ex
; this 
common feature was anticipated given the high similarity of these two classes to their human 
subtype counterparts and their known enrichment for stroma associated genes [14, 23]. The 
aMaSC-MmEnriched signature was most highly expressed in Class14
Ex
 and to a slightly 
lesser extent in Wnt1-Late
Ex
, Wnt1-Early
Ex
, p53null-Basal
Ex
, and Squamous-like
Ex
. The 
fMaSC-MmEnriched signature was most highly expressed in WapINT3
Ex
, which is 
consistent with the finding that Int3 (Notch4) inhibits mammary cell differentiation [30, 31]. 
The LumProg-MmEnriched signature was highest in PyMT
Ex
 and Neu
Ex
. This finding was 
unexpected given that these two mouse classes have been shown to resemble luminal human 
tumors [13, 14]. Lastly, the MatureLum-MmEnriched signature was most highly expressed in 
Stat1
Ex
 and Class14
Ex
. Both the Stat1
-/-
 and Pik3ca-H1047R mouse models, which define 
these two classes respectively, are often ER positive [32, 33], and these data suggest that they 
have mature luminal features. Class14
Ex
 also exhibited significant expression of the aMaSC-
MmEnriched signature, indicating that these tumors contain a mixture or share features of 
multiple cell types. 
Consistent with Figure 11b, 91% of WapINT3
Ex
 tumors were classified as having 
fMaSC features in a nearest centroid predictor analysis. Mouse luminal classes of breast 
carcinoma (Erbb2-like
Ex
, Myc
Ex
, PyMT
Ex
, and Neu
Ex
) were most similar to luminal 
progenitor cells, which again were unexpected but consistent with previous findings [22, 34]. 
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Wnt1-Early
Ex
, p53null-Basal
Ex
 and Squamous-like
Ex
 tumors had primarily aMaSC features. 
Interestingly, Claudin-low
Ex
 and to a lesser extent C3-Tag
Ex
 tumors also had aMaSC features. 
All Stat1
Ex
 tumors had mature luminal features, consistent with being ER positive [32]. 
 
LumProg and fMaSC features predict neoadjuvant chemotherapy response 
Breast tumors respond heterogeneously to neoadjuvant chemotherapy treatment [15]. 
We hypothesized that cellular features of normal mammary subpopulations may identify 
tumors most likely to respond to neoadjuvant chemotherapy. To test this, we compiled a 
dataset of 702 neoadjuvant anthracycline and taxane chemotherapy treated patients (Table 7). 
Although genes within each ‘enriched signature’ are highly correlated within their 
respective normal cell population, it does not necessarily follow that all genes within a given 
normal cell signature would be as coordinately regulated in tumors. Therefore, we subdivided 
each signature into smaller features (feature1, feature2, etc) that are coordinately expressed in 
tumors, reasoning that such refined ‘features’ may be more clinically robust. All ‘enriched’ 
and refined ‘features’ were tested for their ability to predict pCR to neoadjuvant 
chemotherapy in a UVA (Table 8). UVA significant signatures (p<0.05) were then 
considered in a MVA with Age, ER status, PR status, HER2 status, tumor stage, PAM50 
subtype [35], and PAM50 proliferation score [35] to determine if any mammary 
subpopulation ‘features’ added novel information for predicting pCR (Table 9). 
Six normal mammary gene signatures were UVA and MVA significant (Tables 3.5 
and 3.6), with the 95% UVA odds ratio of these six signatures and all other ‘enriched 
signatures’ displayed in Figure 12a. Interestingly, the LumProg-HsEnriched and LumProg-
HsEnriched-feature1 signatures, both of which were highly correlated (Figure 12b), were  
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Table 7: Clinical characteristics of the neoadjuvant chemotherapy treated dataset 
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Table 8: Univariate logistic regression analysis predicting pathological complete 
response in breast cancer patients treated with neoadjuvant anthracycline and taxane 
chemotherapy regimens 
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Table 9: Multivariate logistic regression analysis predicting pathological complete 
response in breast cancer patients treated with neoadjuvant anthracycline and taxane 
chemotherapy regimens 
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Figure 12: fMaSC enriched gene signatures 
a. The univariate logistic regression odds ratio predicting pathologic complete response to 
neoadjuvant anthracycline and taxane chemotherapy was determined using a 702 patient 
dataset, with the 95% confidence interval shown as a forest plot. A single ‘*’ indicates the 
signature was univariate significant, while ‘***’ indicates the signature was both univariate 
and multivariate significant (p<0.05). b. Pearson correlations of multivariate significant gene 
signatures and proliferation were determined. c. The standardized average expression of the 
fMaSC-MmEnriched signature and its two refined signatures was calculated across three 
human datasets and displayed by intrinsic tumor subtype. d. Genes in the fMaSC-
MmEnriched-refined1 signature. E. Genes in the fMaSC-MmEnriched-refined2 signature. 
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highly significant in the UVA and MVA analyses, indicating that tumors with luminal 
progenitor features are more likely to respond to neoadjuvant treatment. Importantly, this 
response was independent of proliferation, as highlighted by their low correlation to the 
PAM50-Proliferation gene signature (Figure 12b). 
Interestingly, the fMaSC-MmEnriched signature refined into two distinctly opposite, 
highly significant signatures in both the UVA and MVA (Table 8, 3.6; Figure 12b, 3.5c). 
While the fMaSC-MmEnriched signature was highest in basal-like tumors, the refined-
signatures varied, with fMaSC-MmEnriched-feature1 (Figure 12d) being highest in basal-like 
tumors and fMaSC-MmEnriched-feature2 (Figure 12e) expressed in luminal tumors. Tumors 
with fMaSC-MmEnriched-feature1 expression were more likely to respond to neoadjuvant 
chemotherapy, while those tumors with fMaSC-MmEnriched-feature2 were more resistant. 
The fMaSC-MmEnriched-feature1 signature was very highly correlated with the LumProg-
HsEnriched signatures (Figure 12b), sharing four genes in common (Figure 12d). These 
results support the hypothesis that subsets of genes within the larger ‘enriched signature’ are 
likely regulated by different biological mechanisms. 
 
DISCUSSION 
 Normal mammary gland physiology is supported by an underlying, complex cell 
hierarchy [2-5]. The simplest model treats differentiation from mammary stem cells to 
progenitor cells to mature cells as unidirectional, but recent observations indicate that 
bidirectional processes are also possible for normal and neoplastic cells [11]. This 
differentiation plasticity may allow tumors to acquire cell features foreign to the initial cell-
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of-origin or to lose native features through the accumulation of specific genetic aberrations 
[36]. 
Regardless of how different cellular traits are acquired, it is critical to identify the 
‘current’ normal cellular features within a tumor, and therefore, we first analyzed the 
expression profiles of normal human and mouse mammary epithelial cell subpopulations [19-
23]. We chose to use nomenclature that maintains continuity with the literature. However, 
these terms should be considered provisional as the complete biological profiles of these 
FACS fractions are investigated  [4].  Recent work by Prater et al [37] found that mouse 
‘luminal progenitor’ cells (CD49f+, EpCAM+) have complete mammary gland repopulating 
potential, indicating that ‘luminal progenitor’ may be a misnomer. Importantly, even if our 
understanding and naming of these cell subpopulations change, only the retrospective 
interpretation of the data presented here will be affected, not the data themselves. 
Using a meta-analysis approach, FACS purified mammary epithelial cell 
subpopulation ‘enriched’ gene signatures were derived and a nearest centroid predictor was 
developed to identify which normal mammary subpopulation each human and mouse tumor 
most represented using over three thousand human patients and 27 mouse models of 
mammary carcinoma [14]. While these analyses imply a cell-of-origin for a given tumor, 
additional experiments (e.g. lineage tracing) will be required to unequivocally determine this. 
Nevertheless, these associations at the very least identify which normal mammary 
subpopulation a given tumor most represents in its current state.  
With this in mind, several associations between both the human and mouse intrinsic 
subtypes and specific normal cell subpopulations were observed. First, human basal-like 
tumors have been referred to as ‘undifferentiated’, which is consistent with their exhibiting 
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luminal progenitor [19] and fetal MaSC features [23]. Three mouse classes have been 
identified to be human basal-like counterparts: Myc
Ex
, p53null-Basal
Ex
, and C3-Tag
Ex
 [14]. 
Myc
Ex
 tumors were the most similar to the luminal progenitor cell profile. By contrast, both 
p53null-Basal
Ex 
and C3-Tag
Ex
 tumors had adult MaSC features. These results indicate that 
Myc
Ex
 tumors share similar cell features as their human basal-like counterpart, making it an 
attractive mouse model for studying basal-like tumors with aberrant Myc signaling [10, 38]. 
Interestingly, neither p53null-Basal
Ex 
nor C3-Tag
Ex
 tumors had strong luminal progenitor 
features, indicating that their association to human basal-like tumors is more likely driven by 
their underlying genetics [10]. 
 Human claudin-low tumors had heterogeneous normal cell features. While most were 
similar to luminal progenitors, the claudin-low subtype also had the largest percentage of 
tumors classified as adult MaSC. Given that claudin-low tumors are enriched with epithelial-
to-mesenchymal transition features [9, 39, 40], our results suggest that these tumors may 
originate from the luminal progenitor population prior to acquiring adult MaSC and/or 
mesenchymal features. Similarly, mouse Claudin-low
Ex
 tumors were also strongly associated 
with the adult MaSC population, indicating that such tumors may be the closest analogs of 
the subset of human claudin-low tumors with adult MaSC features. 
Human HER2-enriched tumors were the most similar to the luminal progenitor 
subpopulation. This is a novel finding and may explain why both human basal-like and 
HER2-enriched subtype tumors show high TP53 mutation frequencies (>70%) and 
widespread chromosomal instability [10]. These data could suggest that the normal luminal 
progenitor cell is somehow extremely dependent upon TP53 function. The murine Erbb2-
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like
Ex
 class has been identified as a mouse counterpart for human HER2-enriched tumors 
[14] and was shown here to also have luminal progenitor features.  
When analyzing the human luminal A and B subtypes, a clear association with 
normal mature luminal cells was observed. The murine Neu
Ex
 class is a proposed counterpart 
for human luminal A tumors [14], yet these mouse tumors were most similar to normal 
mouse luminal progenitor cells. The Myc
Ex
 class was also identified to resemble human 
luminal B tumors [14]. As discussed, Myc
Ex
 tumors have luminal progenitor features; 
therefore, most mouse luminal A/B tumor models do not share the same normal cell features 
as their human tumor counterparts. These differences may reflect limitations of model system 
design, as tumors within these mouse classes are primarily driven by either the WAP or 
MMTV promoter. These differences in cell features, however, indicate that the trans-species 
associations observed previously [14] are possibly driven by the genetics of each mouse 
model. Nevertheless, broad molecular features are conserved between these human-murine 
counterparts [14]. Therefore, we propose that these mouse models retain significant 
preclinical utility provided that shared versus distinct molecular features are taken into 
account. 
Neoadjuvant chemotherapy is a common approach for treating breast tumors, but only 
a relatively low percentage of patients have a pCR (~20% overall). We tested the clinical 
significance of normal cellular features for predicting pCR using a combination of univariate 
and multivariate logistic regression analyses. Human LumProg and mouse fetal MaSC 
expression features were identified as predictive of pCR sensitivity across all breast cancer 
patients. More specifically, LumProg-HsEnriched-feature1 and fMaSC-MmEnriched-
feature1 expression was highest in basal-like tumors. This is consistent with the clinical 
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observation that basal-like tumors have better neoadjuvant chemotherapy response rates since 
higher expression of these normal cell signatures was associated with a higher likelihood of 
pCR. Distinct from these signatures, tumors with high expression of fMaSC-MmEnriched-
feature2 were more resistant to neoadjuvant chemotherapy. Not surprisingly, this signature 
was most highly expressed in luminal A and B tumors, consistent with the clinical 
observation that these subtypes have lower chemotherapy response rates. Importantly, these 
signatures remained significant even after controlling for intrinsic subtype, proliferation, and 
clinical variables in the multivariate analysis; thus these normal cell signatures add 
information even when tumor subtype and clinical features are known. It is presently 
unknown whether tumors with these features arise from a LumProg or fetal MaSC cell-of-
origin or acquire these features during tumorigenesis. Whether these features are acquired or 
inherent, the ‘current’ cellular traits of a tumor are likely most important as these appear to 
be a major determinant of chemotherapy sensitivity. The biological explanation for why 
LumProg and fetal MaSC expression features predict tumor responsiveness to neoadjuvant 
chemotherapy will need to be explored further, but it is likely linked to the common genetic 
features of TP53 loss [41], RB-pathway loss [42], and high proliferation status [43], as well 
as other inherent characteristics of these cellular states. This work highlights the efficacy of 
studying the normal mammary gland cell hierarchy and development in providing insights 
for human tumor therapy responsiveness. 
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MATERIALS AND METHODS 
Mammary cell subpopulation gene signatures 
 Gene expression measurements from fluorescence-activated cell sorting (FACS) 
enriched mammary cell subpopulations were obtained from three human and two murine 
published studies: GSE16997 [19], GSE19446 [22], GSE27027 [23], GSE35399 [20], and 
GSE50470 [21]. The human and murine datasets were separately combined using distance 
weighted discrimination (DWD) normalization to adjust for systemic microarray data biases 
between studies [24]. FACS subpopulation gene signatures were then derived within the 
human and murine dataset separately using a common approach.  First, genes highly 
expressed within each FACS subpopulation were identified using a two-class (subpopulation 
X versus all others) Significance Analysis of Microarrays (SAM) analysis [9, 25], with genes 
highly expressed and with a false discovery rate (FDR) of <5% being considered significant. 
Next, the intersection of each study’s subpopulation gene signature was identified (e.g. 
aMaSC-Lim09 ∩ aMaSC-Shehata ∩ aMaSC-Prat).  The intersecting gene set for each cell 
type was then further limited to genes uniquely found in the subpopulation of interest by 
removing genes found in any other subpopulation’s gene set (e.g. removing members of aStr-
Lim09 ∪ aStr-Shehata ∪ aStr-Prat ∪ LumProg-Lim09 ∪ LumProg-Shehata ∪ LumProg-Prat 
∪ MatureLum-Lim09 ∪ MatureLum-Shehata ∪ MatureLum-Prat from the aMaSC 
intersecting gene set) and by removing genes associated with the myoepithelial 
subpopulation using a published myoepithelial gene signature produced using the same 
approach as those derived here [44]. Through this process, a consensus gene signature was 
produced for each mammary cell FACS subpopulation, for each species, which we 
designated as ‘enriched’ (e.g. aMaSC-HsEnriched). 
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 Each FACS ‘enriched’ signature was further refined by supervised clustering using 
the human UNC308 breast tumor dataset to identify subpopulation ‘features’ [9]. The 
purpose of this process was to identify clusters of genes highly correlated across a diverse 
human tumor dataset, as these gene features are more likely regulated by similar factors and 
therefore, may by more clinically useful than the entire enriched signature. These refined 
features (e.g. fMaSC-feature1 for example) were defined as having at least ten genes with a 
Pearson correlation greater than 0.5 across all tumors in the UNC308 dataset [45]. 
Expression scores for both the ‘enriched’ and ‘feature’ gene signatures were determined by 
calculating the mean expression of the signature within each tumor. Signatures were 
separately standardized to have an average expression value of zero and a standard deviation 
of one (N(0,1)) to allow for across signature comparisons. 
 
Comparison of human and murine normal mammary populations 
 To identify possible commonalities between human and mouse normal mammary 
FACS populations, we used the gene set analysis (GSA) R package v1.03 [46] and R v2.12.2. 
Murine populations were analyzed for significant overlap with each HsEnriched gene 
signature. Significant overlap was defined as having p ≤ 0.05 and FDR ≤ 0.1 to control for 
multiple comparisons [46]. 
 
Mammary cell subpopulation centroids 
Human mammary cell subpopulation centroids were created using the union of the 
‘enriched’ epithelial gene signatures (aMaSC-HsEnriched ∪ LumProg-HsEnriched ∪ 
MatureLum-HsEnriched). The DWD single sample predictor (SSP) function [24] was used to 
77 
 
calculate the shortest Euclidean distance between each tumor and each epithelial cell 
enriched centroid using three human datasets comprising over 3000 patients: UNC308 [9], 
Combined855 [26], and Metabric2136 [27]. To gauge the strength of each mammary 
subpopulation association, the silhouette width was calculated for each sample using R 
v3.0.1 and the ‘cluster’ package. Samples with a positive silhouette width were considered to 
have strong association. Similarly, this process was repeated using the murine cell 
subpopulation dataset to calculate Euclidean distances for a murine expression dataset 
comprising 27 models of mammary carcinoma and normal mammary tissue [14]. 
 
Chemotherapy response 
 Logistic regression analysis was used to determine if gene signatures derived from 
normal cell populations were capable of predicting pathological complete response (pCR) in 
breast cancer patients treated with neoadjuvant anthracycline and taxane chemotherapy 
regimens. For this purpose, a combined breast cancer gene expression dataset was created 
from three public datasets (GSE25066 [47], GSE32646 [48], and GSE41998 [49]). Only 
neoadjuvant anthracycline and taxane treated patients with complete clinical data (Age, ER 
status, PR status, HER2 status, tumor stage and pCR) were considered in the analysis, 
resulting in a dataset of 702 patients. The three datasets were combined using DWD 
normalization to adjust for systemic microarray data biases between studies [24], with the 
clinical characteristics found in Table 7. The significance of each mammary subpopulation 
gene signature and several published predictors of pCR was determined using a series of 
stepwise tests. First, the ability for each signature to predict pCR was determined with a 
univariate analysis (UVA) using R v3.0.1 (Table 8). Those signatures that were significant 
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(p<0.05) were then considered in a multivariate analysis (MVA) with several clinical 
variables (Age, ER status, PR status, HER2 status, tumor stage, PAM50 subtype [35], and 
PAM50 proliferation score [35]) to determine if each mammary subpopulation gene 
signature added new information for predicting pCR (Table 9). 
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CHAPTER 4: SECONDARY GENETIC ABERRATION PROFILING OF P53NULL 
MAMMARY TUMORS HIGHLIGHTS MET DNA AMPLIFICATION AS A GENETIC 
DRIVER OF MURINE BASAL-LIKE TUMORIGENESIS 
 
OVERVIEW 
Background 
Breast cancer is the second leading cause of cancer related deaths in American women. 
Patient care is complicated by inherent tumor heterogeneity that can be classified into at least six 
intrinsic subtypes. While targeted treatments are standard of care for most subtypes, there 
remains a clinical need for targeted therapies against basal-like tumors that are typically ‘triple 
negative breast cancers’. As such, the molecular mechanisms underlying basal-like tumors are 
under intense investigation to identify genetic drivers and possible drug targets of this subtype. 
 
Methods 
Somatic p53 mutations are one of the most common genetic events in basal-like breast 
tumors. This genetic foundation primes cells for secondary genetic aberration accumulation, a 
subset of which are predicted to promote tumorigenesis. To identify additional potential drivers 
of basal-like tumors, a comparative study between human and murine tumors was performed 
utilizing a p53null mammary transplant murine model. Microarray and sequencing technologies 
were used to interrogate the secondary genetic aberrations of these murine tumors to then be 
compared to human basal-like tumors to highlight conserved features. 
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Results 
The p53null mammary murine model produced a genomically diverse set of tumors, a 
subset of which we showed resemble the human basal-like subtype. Of the ‘omic datasets 
analyzed, DNA copy number variation produced the largest number of conserved candidate 
driver genes. Similar to human basal-like tumors, DNA amplification of Met was common to 
murine p53null basal-like tumors. Inhibition of Met using Crizotinib caused these tumors to 
regress, confirming that this genetic event is a driver of murine basal-like tumorigenesis. 
 
Conclusions 
This study identifies Met as a driver of basal-like murine tumors, and thus as a potential 
driver of human basal-like breast cancer. This work also highlights the importance of 
comparative genomic studies for discovering novel drug targets and for determining which 
patient populations are most likely to respond to selective targeted treatments. 
 
BACKGROUND 
 Breast cancer is a heterogeneous disease that can be segregated into at least six distinct 
intrinsic subtypes based on gene expression profiles: basal-like, claudin-low, HER2-enriched, 
luminal A, luminal B, and normal-like [1-3]. While targeted therapeutics exist for estrogen 
receptor positive [4] (luminal A/B [5]) and human epidermal growth factor receptor 2 positive 
[6] (HER2-enriched [5]) tumors, targeted treatments for triple negative breast cancer (TNBC) 
(basal-like and claudin-low [5]) remain an important unmet clinical need [7]. To address this, a 
research emphasis has been placed on identifying the molecular drivers of basal-like and claudin-
low tumors to therefore be exploited as novel drug targets for these subtypes. 
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 Somatic p53 mutations are one of the most frequent genetic events in breast cancer, 
occurring in about 80% of TNBC [3]. While there is a growing appreciation for the 
consequences that p53 gain-of-function mutations impose on cell signaling [8], the majority of 
these mutations are predicted to lead to p53 loss-of-function [9]. This genetic foundation primes 
tumors for secondary genetic aberration accumulation by decreasing the cell’s ability to maintain 
normal cell physiology. Identifying the subset of genetic events that promote breast cancer is 
important for informing tumor biology and for guiding personalized treatment regimens. 
However, segregating genetic drivers of tumorigenesis from passengers is inherently difficult 
due to the diversity of breast tumors and the large number of candidate aberrations identified in 
genome-wide profiling studies [3, 10]. 
 Comparative studies between human and murine tumors provide an attractive approach 
for narrowing the genetic driver candidate list by highlighting conserved features between 
species [11]. The p53null mammary transplant model [12] is a particularly powerful resource for 
identifying the genetic drivers of TNBC. From a genetics perspective, the p53null transplant 
model mimics the loss-of-function seen in human tumors through the expression of a truncated 
version of p53 [13]. In addition, tumors from this model resemble multiple human intrinsic 
subtypes of breast cancer, including both basal-like and claudin-low [11, 14]. Identifying the 
genetic mechanisms that explain this intramodel tumor heterogeneity may help inform the 
etiology of specific human subtypes. From an experimental perspective, the transplantability of 
these tumors allows for a single tumor to be expanded and exhaustively studied to verify that the 
conserved candidates are drivers of tumorigenesis and/or to rigorously test therapeutics [15-18]. 
For these reasons, this study used the p53null mammary transplant model to identify genetic 
drivers, and thus novel drug targets, of basal-like breast tumors. 
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RESULTS 
p53null transplant tumors are counterparts for human basal-like and claudin-low subtypes 
 The p53null transplant model produces phenotypically and genomically diverse tumors 
that can be classified into three major subtypes/classes based on gene expression profiles: 
p53null-Basal
Ex
, Claudin-low
Ex
, and p53null-Luminal
Ex
 [11]. A critical component of breast 
cancer comparative studies is to properly identify corresponding human-to-murine subtype 
counterparts. Once counterparts are determined, conserved features can be identified to highlight 
the candidate genetic drivers that are specific to those subtypes. For this purpose, we used 
several approaches to determine which human subtype each of these three p53null transplant 
genomic classes best represent. 
 First, a transcriptomic comparison between the two species was performed. To do this, 
we created gene signatures for each of our three previously identified p53null transplant classes 
using a two-class (class X versus all others) Significance Analysis of Microarrays (SAM) 
analysis across a 385 sample microarray dataset with 27 murine models of mammary carcinoma 
and normal mammary tissue [11]. Each signature was defined as all genes highly expressed in 
the class of interest with a false discovery rate (FDR) of 0%. The average of these signatures was 
calculated within each sample of the UNC308 [2], Combined855 [19], and Metabric [10] human 
breast cancer datasets to identify which human tumors also highly expressed these same set of 
genes. Interestingly, both the p53null-Basal
Ex
 and p53null-Luminal
Ex
 signatures were highly 
expressed in basal-like human tumors, while the Claudin-low
Ex
 signature was most specific to 
the human claudin-low subtype (Figure 13A). Similar results were observed when we compared 
molecular pathway based signatures (Figure 14A) [11]. 
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Figure 13: Human counterparts of p53null transplant tumors 
A. Genes highly expressed within each p53null transplant class were identified using a 2-class 
(class X vs all others) SAM analysis (FDR 0%) across our 385 murine microarray dataset. The 
standardized average of these gene signatures was calculated across more than three thousand 
human tumors and displayed by intrinsic subtype. B. A representative tumor from each p53null 
transplant class was FAC sorted using antibodies against Epcam and Cd49f. C. 
Immunohistochemistry was performed using antibodies against Krt5 (a marker of basal cells) 
and Krt18 (a marker of luminal cells). 
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Figure 14: Molecular pathway signatures and differentiation score 
A. Median expression values were calculated for 963 publically available pathway-based gene 
signatures across our murine and human expression datasets [11]. Molecular pathway signatures 
were identified using a 2-class (class X vs all others) SAM analysis (FDR 0%) across our 385 
murine microarray dataset. The standardized average of these gene signatures was calculated 
across more than three thousand human tumors and displayed by intrinsic subtype. B. Tumor 
‘differentiation scores’ [2] were calculated for all 385 murine samples and displayed by intrinsic 
class. The ‘differentiation scores’ of the three p53null transplant classes were compared using a 
t-test. 
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 One explanation for the transcriptomic associations observed in Figure 13A is that both 
the human and murine subtypes arise from similar cell types within the mammary gland [20]. To 
address this possibility, a representative tumor from each p53null transplant subtype was selected 
and fluorescence-activated cell sorted (FACS) into its mammary subpopulations using Cd49f and 
Epcam markers [21-23] (Figure 13B). The 2224L (p53null-Basal
Ex
) tumor contained a mixture 
of epithelial cell subpopulations, with 35% of cells being Cd49f
pos
/Epcam
pos
 and 40% of cells 
being Cd49f
double pos
/Epcam
pos
 (Figure 13B). The T11 (p53null-Claudinlow
Ex
) and 2250L 
(p53null-Luminal
Ex
) tumors, however, dissociated into single epithelial subpopulations. 
Specifically, 80% of T11 (p53null-Claudinlow
Ex
) epithelial cells were distinctly 
Cd49f
pos
/Epcam
neg
. Expression profiles of normal human mammary CD49f
pos
/EpCAM
neg
 
subpopulations are enriched within the human claudin-low subtype, indicating that human and 
mouse claudin-low tumors share similar FACS-based cellular features [24]. Greater than 90% of 
2250L (p53null-Luminal
Ex
) epithelial cells were Cd49f
pos
/Epcam
pos
. Human basal-like tumors 
similarly share features of CD49f
pos
/EpCAM
pos
 epithelial cells [23, 24], but tend to show a more 
mixed cellular population as was seen in the murine 2224L (p53null-Basal
Ex
) tumor. 
While these FACS profiles are informative, only a subset of our p53null transplant 
tumors have been properly processed for passaging experiments. As such, we were restricted 
from broadly expanding this approach to all of the tumors in our dataset. To circumvent this 
limitation, a ‘differentiation score’ (D-Score) was calculated for all tumors in the murine 
microarray dataset (Figure 14B) [2]. Low scores indicate a tumor similarity to adult mammary 
stem cells (aMaSC), intermediate scores a similarity to luminal progenitor (LumProg) cells, and 
high scores a similarity to mature luminal (MatureLum) cells [2]. Similar to the individual tumor 
FACS profiles, the D-Score varied across the three p53null subtypes, with the p53null-
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Claudinlow
Ex
 subtype being the lowest, the p53null-Basal
Ex
 being intermediate, and the p53null-
Luminal
Ex
 being the highest (p<0.05) (Figure 14B). Even though the p53null-Luminal
Ex
 subtype 
had the highest D-Score among the three p53null subtypes, its score is still relatively 
intermediate when compared across our diverse murine tumor dataset. This indicates that while 
the p53null-Luminal
Ex
 class is the most ‘luminal’ of the three p53null classes, these tumors do 
not have as strong an association to MatureLum cells as do human luminal A and luminal B 
tumors [24] and murine MMTV-Neu tumors. 
 To supplement these findings, a histological characterization of the cellular features of 
p53null transplant mammary tumors was also performed. Specifically, we stained tumors with 
Krt5 (a marker of basal cells) and Krt18 (a marker of luminal cells). Consistent with the FACS 
profile (Figure 13B), 91% of p53null-Basal
Ex
 tumors were Krt5
pos
/Krt18
pos
, indicating that these 
tumors contain features of both basal and luminal cell types. On the contrary, 66% of p53null-
Claudinlow
Ex
 tumors were Krt5
neg
/Krt18
low
. Consistent with their nomenclature, p53null-
Luminal
Ex
 tumors primarily contained luminal cell type features, with 70% of tumors being 
Krt5
neg
/Krt18
pos
. Taken together (Figure 13), these results indicate that the p53null transplant 
model produces tumors that are best considered murine counterparts for human basal-like and 
claudin-low tumors. 
 
Secondary genetic aberration profiling highlights DNA copy number changes as drivers of 
tumorigenesis 
In broad terms, disruption of normal p53 signaling leads to an unstable genome due to a 
decreased ability to properly respond to the presence of genetic aberrations [25]. This phenotype 
leads to the accumulation of both small scale mutations (e.g. insertions, deletions) and large scale 
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chromosomal rearrangements (e.g. translocations, copy number variations) throughout the 
genome. Specific genetic aberrations are predicted to be responsible for determining a cell’s 
subtype fate during tumorigenesis, but identifying these specific drivers has been challenging. 
Here, we leveraged the power of multiple ‘omic technologies to interrogate the secondary 
genetic aberrations underlying 43 different and independently arisen p53null transplant tumors. 
Specifically, microarray and sequencing technologies were used to produce five datasets of 
varying sizes: DNA exome analysis (EXO) (n=37), DNA copy number (n=43), chromosome 
structural variation (n=37), expression microarrays (n=43), and RNAseq (n=6) (Figure 15). 
 Given our hypothesis that the accumulation of specific secondary genetic events during 
tumorigenesis drives the development of specific tumor subtypes, we designed our statistically 
analyses to identify those genetic events that are enriched within specific p53null transplant 
classes as compared to the other two. Using this approach with our DNA EXO dataset, there 
were no identifiable genes that were somatically mutated and enriched within any of the three 
p53null transplant classes using a 2-class (class X versus all others) fisher’s exact test (Figure 
16). While this was initially a somewhat surprising result, it is consistent with The Cancer 
Genome Atlas’s (TCGA) profiling of human breast tumors in which there was only one gene 
with a mutation frequency greater than ten percent within the basal-like subtype (TP53) [3]. 
 Given the mutation results, we decided to focus on large scale chromosomal 
rearrangements, amplifications, and/or deletions as possible drivers of the p53null transplant 
subtypes. An analysis of chromosome structural variants identified several rearrangements that 
were enriched within each of the three p53null transplant classes using a 2-class (class X versus 
all others) fisher’s exact test (Figure 17). For instance, Mad2l1 was enriched for structural 
rearrangements in p53null-Basal
Ex
 tumors. Mad2l1 plays an important role during metaphase by 
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Figure 15: Murine p53null tumor datasets 
Microarray and sequencing technologies were used to produce five p53null tumor datasets of 
varying sizes: i. DNA SNP (n=37), ii. DNA copy number (n=43), iii. Chromosome structural 
variation (n=37), iv. Expression microarrays (n=43), v. and RNAseq (n=6). The intrinsic class of 
each sample is displayed on the dendrogram, with colored boxes being previously identified 
human subtype counterparts [11]. The hierarchical clustering location of each p53null tumor 
within the datasets is displayed as a vertical black strip.  
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Figure 16: Somatic non-silent mutation analysis 
A. The total number of somatic non-silent mutations was determined for each sample and plotted 
by p53null transplant class. Error bars represent one standard deviation. B. All somatic non-silent 
mutations with a mutational frequency greater than or equal to 8% across all p53null tumors are 
displayed by p53null class. Each row represents an individual tumor, with boxes corresponding 
to a mutation within the gene on that column. 
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Figure 17: Chromosome structural variation analysis 
Displayed are circos plots of the structural variants enriched within A. p53null-Basal, B. p53null-
Claudinlow, and C. p53null-Luminal tumors as determined by 2-class (class X versus all others) 
Fisher’s Exact Tests.  
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preventing progression into anaphase until all chromosomes are properly aligned [26]. 
Overexpression of Mad2l1, as is the case in p53null-Basal
Ex
 tumors (FDR 0%), may further 
promote tumor development by decreasing chromosome stability [27]. While these p53null 
transplant class enriched structural variants are intriguing, it is inherently difficult to perform 
follow-up experiments on these genetic events to gauge their effect on the tumor phenotype. 
Thus, we are unable to definitively call any of these structural variants drivers of these classes. 
 The mechanism by which DNA copy number variation leads to changes in the tumor 
phenotype, however, is more intuitive and more easily tested; therefore, we decided to focus our 
attention on these amplifications and/or deletions as secondary genetic drivers. We were 
primarily interested in identifying genes in which their DNA copy number variation was highly 
correlated with their gene expression, as this observation is consistent with causality. First, we 
identified DNA copy number changes enriched within each of our three p53null transplant 
classes using a 2-class (class X versus all others) SAM analysis (Figure 18). Interesting, both the 
p53null-Basal
Ex
 (Figure 18A) and p53null-Luminal
Ex
 (Figure 18C) classes had distinct genomic 
regions of DNA gains and losses, while the p53null-Claudinlow
Ex
 (Figure 18B) class was more 
copy number neutral, having no genomic regions enriched with gains or losses. These results are 
consistent with human studies which have highlighted several DNA copy number events specific 
to basal-like tumors but few, if any, events in claudin-low tumors [28]. Specifically, p53null-
Basal
Ex
 tumors were defined by both gains and losses on chromosome 8 and almost a complete 
loss of chromosome 12 (Figure 18A), while p53null-Luminal
Ex
 tumors were defined by a DNA 
amplification on chromosome 6 (Figure 18C). 
 To narrow the list of potential genetic drivers within these subtype-specific regions of 
gains and losses, the Pearson correlation between DNA copy number and gene expression was   
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Figure 18: DNA copy number analysis 
Displayed in genomic order are the median class DNA copy number levels for A. p53null-Basal, 
B. p53null-Claudinlow, and C. p53null-Luminal tumors. DNA copy number changes enriched 
within each of the three p53null transplant classes were identified using a 2-class (class X versus 
all others) SAM analysis. Genomic regions of significant gain are labeled in red and regions of 
significant loss are labeled in green. D. Pearson correlations between DNA copy number and 
gene expression were determined for all genes within the significant regions of gain and loss 
from parts A-C. Genes with a correlation greater than or equal to 0.5 are displayed in genomic 
order. The heatmap corresponds to DNA copy number abundance. 
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calculated to highlight the genes that are the most sensitive to DNA gains and losses. In this case, 
genes with Pearson correlations greater than 0.5 were considered to have a strong association 
(Figure 18D). A number of interesting genes fell into this classification. For instance, Inpp4b, a 
regulator of PI3K/AKT signaling [29], was lost in p53null-Basal
Ex
 tumors on chromosome 12, 
similar to human basal-like tumors [28]. Cul4a, which is located on the p53null-Basal
Ex
 
chromosome 8 amplicon, had a very high correlation with its gene expression (Pearson=0.86) 
(Figure 18D and Figure 19A). CUL4A is a scaffolding protein for E3 ubiquitin ligase that helps 
to regulate the cellular concentration of key protein substrates, including CHK1, E2F1, ER-α, 
and pol η to name a few [30]. Given the wide variety of cellular phenotypes that these protein 
substrates influence, such as proliferation and DNA repair [30], CUL4A has been proposed to be 
an attractive cancer drug target [31]. CUL4A amplification and overexpression has been 
observed in the human basal-like breast cancer subtype and has been demonstrated to be a driver 
of tumorigenesis both in-vitro and in-vivo [32-34]. p53null-Luminal
Ex
 tumors had a distinct 
amplification of chromosome 6 (Figure 18C). Within this region, six genes had high correlation 
with their gene expression (Figure 18D), including Met (Pearson=0.92) (Figure 19B). MET is a 
receptor tyrosine kinase for hepatocyte growth factor that regulates a variety of downstream 
signal transduction pathways, including MAPK and PI3K/AKT [35]. 
 Given that both p53null-Basal
Ex
 and p53null-Luminal
Ex
 tumors are counterparts for 
human basal-like tumors (Figure 13), we investigated the TCGA DNA copy number dataset to 
see if these genetic events also frequently occur in human breast tumors. Both MET and CUL4A 
were amplified in ~20% of human basal-like tumors (Table 10). Interestingly, these genetic 
events generally did not co-occur within the same tumor, similar to our p53null mouse model. 
Given that Met DNA amplification is a conserved feature of human and mouse basal-like 
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Figure 19: MET DNA amplification is a driver of 2250L (p53null-Luminal
Ex
) tumors 
A. Pearson correlation between Cul4a DNA copy number and gene expression B. Pearson 
correlation between Met DNA copy number and gene expression C. p53null mammary 
transplant tumor response to Crizotinib treatment 
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Table 10: DNA amplification status of CUL4A and MET across the TCGA breast cancer 
dataset 
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2250L (p53null-Luminal
Ex
) tumors completely regress with Crizotinib treatment 
Similar to Cul4a, Met DNA copy number had a very high correlation with its gene 
expression (Figure 19B). To determine if Met is a driver in Met amplified tumors, noting that 
this gene was not somatically mutated, we treated three p53null transplant tumor lines with 
Crizotinib, a US Food and Drug Administration (FDA) approved therapy for non-small-cell lung 
cancer [36] that inhibits Met and ALK [37]. While neither 2224L (p53null-Basal
Ex
) nor T11 
(p53null-Claudinlow
Ex
) tumors responded to treatment (noting that both of these lines were not 
MET amplified), all of the 2250L (p53null-Luminal
Ex
) tumors had complete regression at the 
end of the 14 day treatment period (Figure 19C). Since Alk is not differentially expressed across 
the three p53null transplant classes, we propose that this dynamic response is due to differences 
in Met signaling, and thus, Met amplification is a driver of tumorigenesis in this mouse model of 
basal-like breast cancer. 
 
DISCUSSION 
Even though increased public awareness and a greater understanding of tumor biology 
have led to improved patient survival rates, breast cancer is still the second leading cause of 
cancer related deaths in American women. With so many patients either not responding or 
relapsing with the current standard of care, the molecular mechanisms underlying breast cancer 
are under intense investigation to identify new, personalized drug targets [38, 39]. This is 
especially true for triple negative breast cancer (TNBC) (basal-like and claudin-low) for which 
targeted treatment options remain an important unmet clinical need. Murine models provide an 
excellent resource for identifying genetic drug targets by highlighting conserved features 
between species [11]. Given that somatic p53 mutations are one of the most common genetic 
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events in TNBC [3], the p53null mammary transplant mouse model is particularly useful for 
studying the molecular mechanisms of TNBCs. 
 The p53null transplant model produces heterogeneous tumors that can be classified into 
three major subtypes/classes based on gene expression profiles: p53null-Basal
Ex
, Claudin-low
Ex
, 
and p53null-Luminal
Ex
 [11]. Using a combination of gene expression comparisons, FACS 
analysis, and immunohistochemistry, we show that p53null-Basal
Ex
 and p53null-Luminal
Ex
 
tumors are counterparts for the human basal-like subtype, while p53null-claudinlow
Ex
 tumors are 
counterparts for the human claudin-low subtype. Even though p53null-Luminal
Ex
 tumors were 
the most ‘luminal’ of the p53null classes, these tumors were found to more closely resemble 
luminal progenitor cells than mature luminal cells. Specifically, FACS analysis of the 2250L 
(p53null-Luminal
Ex
) line indicated that this tumor is Cd49f
pos
/Epcam
pos
, the same FACS profile 
as luminal progenitor cells [23]. In addition, p53null-Luminal
Ex 
tumors have intermediate 
‘differentiation scores’, similar to luminal progenitor cells [2]. The original nomenclature for this 
class was derived by an observed association to the luminal subtypes based on a few luminal 
markers [14], but recent work has shown that mature luminal and luminal progenitor cells share 
many of the same features [24, 40]. For instance, both FACS populations are EpCAM
pos
 and 
Krt18
pos
 [23, 40], indicating that broader analyses are required to distinguish between these cell 
types within tumors. These findings help explain why p53null-Luminal tumors were found to be 
counterparts for the basal-like subtype and not the luminal A/B subtypes, as basal-like tumors 
also share features of luminal progenitor cells [23, 24]. 
Once these human-murine subtype counterparts were defined, secondary genetic 
aberration profiling was performed to identify conserved events between species to highlight 
candidate drivers of tumorigenesis. Of the ‘omic datasets analyzed, DNA copy number variation 
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produced the largest number of candidate genes. We were particularly interested in genes that 
had high correlation between their copy number and gene expression because for these cases, we 
propose that the copy number change is the mechanism that directly influences the expression of 
the genes within those genomic regions. 
The murine p53null-Luminal
Ex
 class showed a reproducible amplification of MET 
(without mutation), thus suggesting that this could be a driving event for this murine subtype. 
Crizotinib treatment resulted in complete tumor regression (not palpable) at the end of the 14 day 
treatment period in our 2250L (p53null-Luminal
Ex
) tumor line. MET is an important receptor 
tyrosine kinase that can activate a variety of signal transduction pathways, including MAPK and 
PI3K/AKT. These results suggest that MET is a driving oncogene in this subtype, and that 
Crizotinib may perform very well as a single agent against breast tumors with aberrant MET 
signaling. These experimental results are particularly relevant given that about 20% of human 
basal-like tumors have amplification of MET. Since not all basal-like patients have these 
aberrations, companion diagnostic tests will be required to determine which patients should 
receive treatment which, in this case, could be based upon the presence or absence of MET 
amplification. Proper clinical studies will be required to determine if that is the case. 
 In summary, we identified a number of class specific copy number events in our p53null 
mouse model, which mimicked similar events in human basal-like tumors. Using a comparative 
genomics approach, this study identified MET as a driver of one of these mouse classes and 
highlights the potential link of MET to human basal-like breast cancer [35]. In addition to this 
clinically important finding, it also highlights the importance of comparative genomic studies as 
a preclinical tool for discovering novel drug targets and for determining which patient 
populations are most likely to respond to treatment. Currently, only ~5% of oncology drugs that 
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enter clinical testing are ultimately approved by the US FDA for use [41]. From a financial 
perspective, this low success rate means that it cost more than $1,000,000,000 of research and 
development spending to develop a single oncology drug [42]. Needless to say, improved 
methods are needed to streamline the drug development process and to lower healthcare costs. 
As supported by the results of this study, we propose that mouse models should be an integral 
part of early phase drug development to highlight those drug/drug combinations most likely to 
succeed in clinical trials. 
 
MATERIALS AND METHODS 
Gene expression 
 Microarray gene expression data from 27 murine models of mammary carcinoma and 
normal mammary tissue were downloaded from the following gene expression omnibus (GEO) 
entries: GSE3165, GSE8516, GSE9343, GSE14457, GSE15263, GSE17916, GSE27101, and 
GSE42640 [11]. The 385 sample dataset was normalized to correct for microarray platform bias 
as previously described [11]. 
 Tumor differentiation scores were calculated across the microarray dataset as previously 
described [2]. Gene expression signatures were created for the three murine classes enriched with 
the p53null transplant model (p53null-Basal
Ex
, Claudin-low
Ex
, and p53null-Luminal
Ex
) by 
performing a two-class (class X versus all others) Significance Analysis of Microarrays (SAM) 
analysis on the microarray dataset [43]. Signatures were defined as all genes highly expressed in 
the class of interest with a false discovery rate (FDR) of 0%. Similarly, pathway signatures were 
created as previously described [11]. Expression scores for each gene and pathway signature 
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were determined by calculating the mean expression of the signature within each sample in the 
UNC308 [2], Combined855 [19], and Metabric [10] human breast cancer datasets.  
  
Flow cytometry 
p53null transplant tumors were dissociated into a single cell suspension using the 
following steps. First, each tumor was manually cut into small pieces with a razor blade in 1X 
collagenase/hyaluronidase (StemCell #07919) EpiCult media (StemCell #05601) before being 
placed in a rotator for two hours at 37
o
C. Following lysis of red blood cells using ammonia 
chloride (StemCell #07850), the tumors were incubated in 1X trypsin-EDTA (Sigma #T4049) 
for five minutes at 37
o
C and then in a 1X Dispase (StemCell #07923) DNase I solution 
(StemCell #07900) for five min at 37
o
C to reduce cell clumping. Cells were filtered through a 
40µm nylon cell strainer (Fisher Scientific #08-771-1) in HBSS media (StemCell #37150) with 
10% FBS (Sigma #F2442) to obtain the final single cell suspension. To remove non-epithelial 
cells, the single cell suspension was taking through a mouse epithelial cell enrichment kit 
(StemCell #19758) following the manufacturer’s protocol. Cells were labeled with the following 
antibodies for 30 minutes at 4
o
C: FITC anti-mouse Epcam (eBioscience #11-5791-82) and APC 
anti-mouse Cd49f (eBioscience #17-0495-82). Fluorescence-activated cell sorting (FACS) was 
performed using a Beckman-Coulter CyAn ADP instrument and analyzed using the FlowJo v10 
software program. 
 
DNA single nucleotide polymorphisms 
Mutation data was collapsed to a gene level so that all non-silent somatic mutations 
affecting the same gene were treated equally regardless of the actual mutation. A two-class (class 
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X versus all others) fisher’s exact test (FET) was performed to identify genes preferentially 
mutated within each p53null class (p-value<0.05). 
 
DNA structural variants 
Genomic structural variants (SV) were collapsed to a gene level so that all SV affecting 
the same gene were treated equally regardless of the actual SV. Genes were defined as being 
affected by the structural variant if the start or end of the SV occurred within the RefSeq gene 
region. A two-class (class X versus all others) FET was performed to identify genes 
preferentially affected by SV within each p53null class (p-value<0.05). Because all of the 
p53null Claudin-low
Ex
 tumors were analyzed using whole genome sequencing, a second two-
class FET was performed on these tumors in which only the 13 whole genome profiled tumors 
were included in the analysis to reduce the likelihood of the p53null Claudin-low
Ex 
enriched SV 
being an artifact of methodology. 
 
DNA copy number 
 DNA array comparative genomic hybridization (aCGH) data was downloaded for the 
p53null transplant tumors classified as p53null-Basal
Ex
, Claudin-low
Ex
, or p53null-Luminal
Ex 
by 
gene expression profiling from GEO entry GSE27101 [14]. In addition, genomic DNA was 
extracted from five p53null transplant tumors using a DNeasy blood and tissue kit (Qiagen 
#69504), labeled with a Sure Tag DNA kit (Agilent #5190-4240), and hybridized to 244K CGH 
microarrays (Agilent #G4415A) as previously described [14]. 
The 43 sample aCGH dataset was extracted from the UNC Microarray Database as log2 
Cy5/Cy3 ratios, filtering for probes with Lowess normalized intensity values greater than ten in 
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the control channel and for probes with data on greater than 70% of the microarrays [14]. The 
probes that passed these filters where then oriented in genomic order and a ten probe average 
was calculated on consecutive groups of ten probes across each chromosome, resulting in a final 
dataset of 23,181 features. A two-class (class X versus all others) SAM analysis was performed 
to identify genomic regions of amplification or deletion unique to each class (FDR of 0%). 
 Level 3 DNA segmentation data was downloaded from The Cancer Genome Atlas 
(TCGA) data portal for 715 breast cancer samples. Genomic regions of amplification were 
defined as having a log2 segmentation value greater than 0.3. 
 
Crizotinib treatment 
 All mouse work was performed under protocols approved by the UNC Institutional 
Animal Care and Use Committee (IACUC). One million p53null transplant cells were suspended 
in matrigel and injected subcutaneously into the mammary pad of BALB/c wild-type female 
mice. Upon tumor formation, mice were randomized to either the Crizotinib (ChemShuttle 
#877399-52-5) or untreated group. Crizotinib chow was synthesized by OpenSource Diets to a 
final concentration of 50 mg/kg/day and was given continuously over the 14 day treatment 
period to monitor tumor growth. Tumor volume was calculated from two-dimensional 
measurements (Volume = [(width)
2
 x length]/2). The percent change in volume at 14 days was 
used to quantify response. 
108 
 
REFERENCES 
1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross 
DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. 
Nature 2000, 406:747-752. 
 
2. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM: 
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of 
breast cancer. Breast Cancer Res 2010, 12:R68. 
 
3. Cancer Genome Atlas N: Comprehensive molecular portraits of human breast 
tumours. Nature 2012, 490:61-70. 
 
4. Jordan VC: Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 
2003, 2:205-213. 
 
5. Prat A, Perou CM: Deconstructing the molecular portraits of breast cancer. Mol 
Oncol 2011, 5:5-23. 
 
6. Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of targeted 
inhibitors. Nat Rev Cancer 2005, 5:341-354. 
 
7. Carey L, Winer E, Viale G, Cameron D, Gianni L: Triple-negative breast cancer: 
disease entity or title of convenience? Nat Rev Clin Oncol 2010, 7:683-692. 
 
8. Brosh R, Rotter V: When mutants gain new powers: news from the mutant p53 field. 
Nat Rev Cancer 2009, 9:701-713. 
 
9. Bullock AN, Fersht AR: Rescuing the function of mutant p53. Nat Rev Cancer 2001, 
1:68-76. 
 
10. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, 
Samarajiwa S, Yuan Y, et al: The genomic and transcriptomic architecture of 2,000 
breast tumours reveals novel subgroups. Nature 2012, 486:346-352. 
 
11. Pfefferle AD, Herschkowitz JI, Usary J, Harrell JC, Spike BT, Adams JR, Torres-
Arzayus MI, Brown M, Egan SE, Wahl GM, et al: Transcriptomic classification of 
genetically engineered mouse models of breast cancer identifies human subtype 
counterparts. Genome Biol 2013, 14:R125. 
 
12. Jerry DJ, Kittrell FS, Kuperwasser C, Laucirica R, Dickinson ES, Bonilla PJ, Butel JS, 
Medina D: A mammary-specific model demonstrates the role of the p53 tumor 
suppressor gene in tumor development. Oncogene 2000, 19:1052-1058. 
 
13. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg 
RA: Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994, 4:1-7. 
109 
 
 
14. Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, Knezevic J, 
Greene SB, Darr D, Troester MA, et al: Comparative oncogenomics identifies breast 
tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci U S A 2012, 
109:2778-2783. 
 
15. Roberts PJ, Bisi JE, Strum JC, Combest AJ, Darr DB, Usary JE, Zamboni WC, Wong 
KK, Perou CM, Sharpless NE: Multiple roles of cyclin-dependent kinase 4/6 
inhibitors in cancer therapy. J Natl Cancer Inst 2012, 104:476-487. 
 
16. Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, Whittle MC, Duncan JS, 
Johnson SM, Combest AJ, Jin J, et al: Combined PI3K/mTOR and MEK inhibition 
provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res 
2012, 18:5290-5303. 
 
17. Usary J, Zhao W, Darr D, Roberts PJ, Liu M, Balletta L, Karginova O, Jordan J, Combest 
A, Bridges A, et al: Predicting drug responsiveness in human cancers using 
genetically engineered mice. Clin Cancer Res 2013, 19:4889-4899. 
 
18. Bennett CN, Tomlinson CC, Michalowski AM, Chu IM, Luger D, Mittereder LR, 
Aprelikova O, Shou J, Piwinica-Worms H, Caplen NJ, et al: Cross-species genomic and 
functional analyses identify a combination therapy using a CHK1 inhibitor and a 
ribonucleotide reductase inhibitor to treat triple-negative breast cancer. Breast 
Cancer Res 2012, 14:R109. 
 
19. Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, Anders C, Ewend M, Perou CM: 
Genomic analysis identifies unique signatures predictive of brain, lung, and liver 
relapse. Breast Cancer Res Treat 2012, 132:523-535. 
 
20. Visvader JE: Keeping abreast of the mammary epithelial hierarchy and breast 
tumorigenesis. Genes Dev 2009, 23:2563-2577. 
 
21. Prat A, Karginova O, Parker JS, Fan C, He X, Bixby L, Harrell JC, Roman E, Adamo B, 
Troester M, Perou CM: Characterization of cell lines derived from breast cancers and 
normal mammary tissues for the study of the intrinsic molecular subtypes. Breast 
Cancer Res Treat 2013, 142:237-255. 
 
22. Shehata M, Teschendorff A, Sharp G, Novcic N, Russell IA, Avril S, Prater M, Eirew P, 
Caldas C, Watson CJ, Stingl J: Phenotypic and functional characterisation of the 
luminal cell hierarchy of the mammary gland. Breast Cancer Res 2012, 14:R134. 
 
23. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, 
Ward T, Partanen A, et al: Aberrant luminal progenitors as the candidate target 
population for basal tumor development in BRCA1 mutation carriers. Nat Med 
2009, 15:907-913. 
 
110 
 
24. Pfefferle AD, Spike BT, Wahl GM, Perou CM: Luminal progenitor and fetal 
mammary stem cell expression features predict breast tumor response to 
neoadjuvant chemotherapy. Breast Cancer Res Treat 2015, 149:425-437. 
 
25. Bieging KT, Mello SS, Attardi LD: Unravelling mechanisms of p53-mediated tumour 
suppression. Nat Rev Cancer 2014, 14:359-370. 
 
26. Schvartzman JM, Sotillo R, Benezra R: Mitotic chromosomal instability and cancer: 
mouse modelling of the human disease. Nat Rev Cancer 2010, 10:102-115. 
 
27. Sotillo R, Hernando E, Diaz-Rodriguez E, Teruya-Feldstein J, Cordon-Cardo C, Lowe 
SW, Benezra R: Mad2 overexpression promotes aneuploidy and tumorigenesis in 
mice. Cancer Cell 2007, 11:9-23. 
 
28. Weigman VJ, Chao HH, Shabalin AA, He X, Parker JS, Nordgard SH, Grushko T, Huo 
D, Nwachukwu C, Nobel A, et al: Basal-like Breast cancer DNA copy number losses 
identify genes involved in genomic instability, response to therapy, and patient 
survival. Breast Cancer Res Treat 2012, 133:865-880. 
 
29. Agoulnik IU, Hodgson MC, Bowden WA, Ittmann MM: INPP4B: the new kid on the 
PI3K block. Oncotarget 2011, 2:321-328. 
 
30. Jackson S, Xiong Y: CRL4s: the CUL4-RING E3 ubiquitin ligases. Trends Biochem 
Sci 2009, 34:562-570. 
 
31. Sharma P, Nag A: CUL4A ubiquitin ligase: a promising drug target for cancer and 
other human diseases. Open Biol 2014, 4:130217. 
 
32. Chen LC, Manjeshwar S, Lu Y, Moore D, Ljung BM, Kuo WL, Dairkee SH, Wernick M, 
Collins C, Smith HS: The human homologue for the Caenorhabditis elegans cul-4 
gene is amplified and overexpressed in primary breast cancers. Cancer Res 1998, 
58:3677-3683. 
 
33. Gupta A, Yang LX, Chen L: Study of the G2/M cell cycle checkpoint in irradiated 
mammary epithelial cells overexpressing Cul-4A gene. Int J Radiat Oncol Biol Phys 
2002, 52:822-830. 
 
34. Saucedo-Cuevas LP, Ruppen I, Ximenez-Embun P, Domingo S, Gayarre J, Munoz J, 
Silva JM, Garcia MJ, Benitez J: CUL4A contributes to the biology of basal-like breast 
tumors through modulation of cell growth and antitumor immune response. 
Oncotarget 2014, 5:2330-2343. 
 
35. Gastaldi S, Comoglio PM, Trusolino L: The Met oncogene and basal-like breast 
cancer: another culprit to watch out for? Breast Cancer Res 2010, 12:208. 
 
111 
 
36. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, 
Paolini J, Usari T, et al: First-line crizotinib versus chemotherapy in ALK-positive 
lung cancer. N Engl J Med 2014, 371:2167-2177. 
 
37. Shaw AT, Yasothan U, Kirkpatrick P: Crizotinib. Nat Rev Drug Discov 2011, 10:897-
898. 
 
38. Curigliano G, Goldhirsch A: The triple-negative subtype: new ideas for the poorest 
prognosis breast cancer. J Natl Cancer Inst Monogr 2011, 2011:108-110. 
 
39. Curigliano G: New drugs for breast cancer subtypes: Targeting driver pathways to 
overcome resistance. Cancer Treat Rev 2011, 38:303-310. 
 
40. Kannan N, Huda N, Tu L, Droumeva R, Aubert G, Chavez E, Brinkman RR, Lansdorp P, 
Emerman J, Abe S, et al: The luminal progenitor compartment of the normal human 
mammary gland constitutes a unique site of telomere dysfunction. Stem Cell Reports 
2013, 1:28-37. 
 
41. Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nat Rev 
Drug Discov 2004, 3:711-715. 
 
42. Scannell JW, Blanckley A, Boldon H, Warrington B: Diagnosing the decline in 
pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012, 11:191-200. 
 
43. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the 
ionizing radiation response. Proc Natl Acad Sci U S A 2001, 98:5116-5121. 
 
112 
 
CHAPTER 5: THE MMTV-WNT1 MURINE MODEL PRODUCES TWO 
PHENOTYPICALLY DISTINCT SUBTYPES OF MAMMARY TUMORS WITH 
UNIQUE CLINICAL OUTCOMES TO EGFR INHIBITORS 
 
OVERVIEW 
Background  
The Wnt gene family is an evolutionarily conserved group of proteins that regulate cell 
growth, differentiation, and stem cell self-renewal. Aberrant Wnt signaling in human breast 
tumors has been proposed to be an attractive drug target, especially in the basal-like subtype 
where canonical Wnt signaling is both enriched and predictive of poor clinical outcomes. The 
development of effective Wnt based therapeutics, however, has been slowed in part by a limited 
understanding of the context dependent nature with which these aberrations influence breast 
tumorigenesis. 
 
Methods  
MMTV-Wnt1 mice are an established model for studying Wnt signaling in breast tumors. 
We recently reported that this model develops two subtypes of tumors by gene expression 
classification: Wnt1-Early
Ex
 and Wnt1-Late
Ex
. Here, we validate this initial observation using a 
combination of histology, fluorescence-activated cell sorting (FACS), limiting dilution assays, 
mutation analysis, gene expression profiling, and drug treatments to compare the phenotypes of 
these two Wnt1 tumor subtypes. 
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Results  
Wnt1-Early
Ex
 tumors have high expression of canonical Wnt, non-canonical Wnt, and 
EGFR signaling pathway signatures. Therapeutically, Wnt1-Early
Ex
 tumors had a dynamic 
reduction in tumor volume when treated with EGFR inhibitors. Wnt1-Early
Ex
 tumors had 
primarily Cd49f
+
/Epcam
-
 FACS profiles, but were unable to be serially transplanted into wild-
type FVB female mice. Wnt1-Late
Ex
 tumors, conversely, had a bloody gross pathology, which is 
highlighted by the presence of ‘blood lakes’ by H&E staining. These tumors had primarily 
Cd49f
+
/Epcam
+
 FACS profiles, but also contained a secondary Cd49f
+
/Epcam
-
 subpopulation. 
Both Wnt1-Late
Ex
 FACS subpopulations contained activating Hras1 mutations and were capable 
of individually reproducing tumors when serially transplanted into wild-type FVB female mice.  
 
Conclusions 
This study definitely shows that the MMTV-Wnt1 mouse model produces two 
phenotypically distinct subtypes of mammary tumors. Importantly, these subtypes differ in their 
therapeutic response to EGFR inhibitors, suggesting that a subset of human tumors with aberrant 
Wnt signaling may also respond to these drugs. 
 
BACKGROUND 
 The mammalian breast is a unique organ capable of dynamic morphologic and 
physiologic change during organogenesis, puberty, pregnancy, lactation, and involution [1]. 
These processes are supported by a breast morphology that can be subdivided into four primary 
compartments: the stroma, the basement membrane, the basal layer, and the luminal layer [2, 3]. 
Within each of these compartments reside specific cell types that together form a mammary cell 
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hierarchy [4-6]. Specifically, the stroma consists primarily of fibroblasts, adipocytes, and 
immune cells [3, 7]. The basal layer is enriched for myoepithelial cells and mammary stem cells 
(MaSC) [8] and the luminal layer contains a combination of estrogen receptor (ER) positive and 
ER negative mature luminal cells [3]. 
 Each cell within this hierarchy has developed specialized functions to support the 
necessary changes that will occur over a woman’s lifetime. These processes include important 
elements of paracrine signaling to transmit signals across the different mammary compartments 
to specific recipients [9]. The Wnt family is an evolutionarily conserved group of proteins that 
promote paracrine signal transduction through at least five different pathways [2]. The canonical 
Wnt pathway signals through Frizzled (Fzd) and LDL-receptor-related (Lrp) co-receptors (Lrp5 
and Lrp6) to activate Beta-catenin transcriptional regulation of key genes [2], such as c-Myc 
[10], c-Jun [11], and Vegf [12]. The other Wnt-regulated pathways are collectively referred to as 
non-canonical Wnt signaling. These include calcium and planar cell polarity signaling through 
Fzd receptors, Jnk signaling through the Ror2 receptor and Src signaling through the Ryk 
receptor [2]. While these pathways are commonly described from a cell autonomous perspective, 
complex signaling patterns emerge when paracrine signaling is considered [9]. In addition, there 
are 19 Wnt ligands and 10 Fzd receptors. When taking into account co-receptors and cell type 
specific expression patterns [13, 14], a large number of combinations are possible. Given the 
importance of Wnt signaling for controlling cell growth, differentiation, and stem cell self-
renewal [15], a research emphases has been placed on better understanding these Wnt signaling 
pathways.  
 One area of particular focus has been determining how aberrant Wnt signaling influences 
breast tumor formation and progression. Breast cancer is a heterogeneous disease that can be 
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segregated into at least six distinct intrinsic subtypes based on gene expression profiles: basal-
like, claudin-low, HER2-enriched, luminal A, luminal B, and normal-like [16-18]. Interestingly, 
canonical Wnt signaling is enriched in basal-like breast tumors [19]. These patients also tend to 
have a poor clinical outcome [19], suggesting Wnt signaling as a potential therapeutic target 
[15]. Unlike colorectal cancer where inappropriate Wnt pathway activation is associated with 
gene mutations [20], mutations affecting Wnt associated genes are uncommon in breast tumors 
[18]. Instead, activation in breast tumors is proposed to occur through the downregulation of 
negative Wnt pathway regulators, such as secreted frizzle-related proteins [21, 22]. Even though 
these pathways have been highly examined, more research is needed to fully untangle the 
complex behavior of these signaling molecules. For instance, the molecular mechanisms that 
explain how paracrine Wnt signaling can induce growth of some tumors and inhibit it in others 
have remained elusive [23]. 
 Genetically engineered mouse models are a useful resource for studying mammary 
tumors in vivo under genetically controlled and immune competent conditions [24]. MMTV-
Wnt1 mice are particularly useful for modeling Wnt signaling in breast tumors [25, 26]. These 
tumors are comprised of mixed-lineage subclonal populations, having features of both luminal 
and basal epithelial cells [27]. In a subset of MMTV-Wnt1 tumors, cooperation between both 
subclonal populations is required for tumor propagation [27], highlighting this model as a tool 
for studying Wnt paracrine signaling and intratumoral heterogeneity [28]. We recently reported 
that MMTV-Wnt1 mice develop two subtypes/classes of tumors based on gene expression 
profiling [29], a finding that is surprisingly underrepresented in the vast literature on this model. 
Here, we investigate the significance of our prior observation and show that that these two 
classes of tumors have distinct phenotypes. Importantly, drug treatment experiments confirmed 
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that these subtypes had substantial response differences, thus shedding additional light on the 
significance of the Wnt pathway. 
 
RESULTS 
Even though the Wnt family has been highly studied from both developmental and 
oncology perspectives, the complexity of this pathway has hindered a complete understanding of 
the molecular mechanisms that regulate cell growth, differentiation, and stem cell self-renewal 
[15]. The MMTV-Wnt1 murine model is attractive for studying aberrant Wnt signaling in breast 
carcinoma [25, 26]. Interestingly, we find that these mice have a broad distribution of tumor 
latencies, developing as early as 5 weeks of age and as late as 58 weeks of age (Figure 20A). A 
histogram of 172 tumor latencies produces a bimodal distribution, with an ‘early’ local 
maximum around 7.5 weeks and a ‘late’ local maximum around 21.5 weeks. Even though no 
differences were observed on a DNA copy number level (Figure 21), gene expression profiling 
found that these Wnt-Early
Ex
 and Wnt1-Late
Ex
 tumors have distinct biological features [29], 
indicating that this tumor latency distribution is more than just a stochastic event (Figure 20B). 
Given these findings, we performed an in depth comparison of these two Wnt1 tumor classes to 
further our understanding of the clinical significance of Wnt signaling in breast carcinoma. 
 
Wnt1-Early
Ex
 and Wnt1-Late
Ex
 tumors have distinct gross pathology and histology traits 
 In addition to being classified into different molecular expression subtypes/classes, 
Wnt1-Early
Ex
 and Wnt1-Late
Ex
 tumors were also found to have distinct gross pathological 
features. Specifically, Wnt1-Early
Ex 
tumors tended to show a dense cellular morphology and be 
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Figure 20: The MMTV-Wnt1 model produce two classes of mammary tumors with distinct 
latencies, gross pathology and histology features  
A. MMTV-Wnt1 tumor latency histogram by week B. Dendrogram of a hierarchical cluster of all 
murine tumors in our dataset using a previously defined intrinsic gene list [29]. Boxes 
correspond to previously defined murine intrinsic subtypes/classes [29]. C. Gross pathology of 
representative Wnt1-Early
Ex
 and Wnt1-Late
Ex
 tumors. D. H&E staining of representative Wnt1-
Early
Ex
 and Wnt1-Late
Ex
 tumors. E. Standardized expression of a hypoxia gene signature [30] 
across mouse class. F. Krt5 and Krt8/18 staining of representative Wnt1-Early
Ex
 and Wnt1-
Late
Ex
 tumors. G. Krt5 and Krt8/18 staining of representative Wnt1-Early
Ex
 tumors. H. Relative 
tumor fraction of Krt5 positive and Krt8/18 positive cells. 
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Figure 21: Wnt1-Early
Ex
 and Wnt1-Late
Ex
 have similar DNA copy number landscapes 
Displayed in genomic order are the median class DNA copy number levels for A. Wnt1-Early
Ex
 
and B. Wnt1-Late
Ex
 tumors. 
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more resistant to incision, while Wnt1-Late
Ex 
tumors appeared to be more necrotic and often 
filled with pockets of blood (Figure 20C). Importantly, these characteristics were found to be 
irrespective of tumor size at the time of collection, indicating that these observations were not a 
technical artifact but inherent to the tumors themselves. These gross pathological differences 
were recapitulated with hematoxylin and eosin (H&E) staining in which Wnt1-Late
Ex
 tumors had 
characteristic ‘blood lake’ regions as highlighted by black arrows in Figure 20D. These different 
vascular traits led us to hypothesize that Wnt1-Early
Ex
 tumors should be more hypoxic than 
Wnt1-Late
Ex
 tumors. In support of this, a VEGF/Hypoxia gene signature [30] is highly expressed 
in Wnt1-Early
Ex
 tumors and lower expressed in Wnt1-Late
Ex
 tumors. 
 It is well documented that MMTV-Wnt1 tumors are comprised of mixed-lineage 
subclonal populations, having features of both luminal and basal cells [27]. To investigate the 
relative fraction of these subclonal populations, immunofluorescence staining was performed 
using antibodies against Krt5 (a marker of basal cells) and Krt8/18 (a marker of luminal cells). 
Consistent with the literature, both Wnt1-Early
Ex
 and Wnt1-Late
Ex
 tumors stained positive for 
both cell populations (Figure 20F). Unlike Wnt1-Late
Ex
, Wnt1-Early
Ex
 tumors had distinct 
regions that did not stain positive for either Krt5 or Krt8/18 (Figure 20G). These areas did stain 
positive for DAPI, indicating that there are cells within these regions. When measuring the 
relative tumor fractions of these populations, it is observed that Wnt1-Late
Ex
 tumors contained a 
higher fraction of Krt5 positive cells (p=0.02) and Krt8/18 positive cells (p=0.001) than Wnt1-
Early
Ex
 tumors (Figure 20H). Combined, these two cell fractions comprised about 100% of 
Wnt1-Late
Ex
 tumors. For Wnt1-Early
Ex 
tumors, these two fractions only accounted for only about 
65% of the tumor, with the remaining 35% consisting of regions that did not stain positive for 
either Krt5 or Krt8/18. Further experiments, such as laser capture microdissection (LCM), will 
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be needed to determine the biological significance of these heterogeneously staining (or not 
staining) tumor regions. 
 
Wnt1-Early
Ex
 tumors are enriched for canonical and non-canonical Wnt pathway 
signatures 
 Wnt signal transduction can occur through several different molecular pathways, 
including canonical Wnt, Jnk, and Src [2]. To investigate these pathways in our mouse tumors, 
expression based pathway gene signatures were used to estimate pathway activity [29, 31]. As a 
good positive control, the canonical KEGG WNT signaling pathway was the most highly 
expressed in both Wnt1-Early
Ex
 and Wnt1-Late
Ex
 classes (Figure 22A). Interestingly, this 
pathway signature is higher expressed in Wnt1-Early
Ex
 compared to Wnt1-Late
Ex
 tumors 
(p=0.02). This observation does not appear to be a result of variation in Wnt1 transgene 
expression, as there was no statistical difference between the Wnt1-Early
Ex
 and Wnt1-Late
Ex
 
classes for the single Wnt1 probe (exon 4) in our combined murine dataset (Figure 22B). A 
closer investigation into the individual genes within the canonical KEGG WNT signaling 
pathway identified several differentially expressed genes between Wnt1-Early
Ex
 and Wnt1-
Late
Ex
 tumors (Figure 22B). Canonical Wnt signaling occurs through Frizzled (Fzd) and LDL-
receptor-related (Lrp) co-receptors [2]. Fzd receptors Fzd1, Fzd2, Fzd9, and Fzd10 are higher 
expressed in Wnt1-Early
Ex
 tumors, while Fzd5 is higher in Wnt1-Late
Ex
 tumors (FDR 0%). In 
addition, the Lef1 transcription factor and its target, c-Jun [11], are also higher expressed in 
Wnt1-Early
Ex
 tumors (FDR 0%). These results are consistent with higher canonical Wnt pathway 
activity in Wnt1-Early
Ex
 tumors. 
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Figure 22: Wnt-Early
Ex
 tumors have expression of Wnt associated pathway signatures  
A. Standardized expression of the KEGG Wnt signaling pathway signature across mouse class. 
B. Schematic of the KEGG Wnt signaling pathway. C. Standardized expression of the ST JNK 
MAPK signaling pathway signature across mouse class. D. Standardized expression of the 
Biocarta SRC signaling pathway signature across mouse class. 
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 In addition to higher expression of the canonical KEGG WNT signaling pathway 
signature, Wnt1-Early
Ex
 tumors also have higher expression of non-canonical Wnt signaling 
pathway signatures: ST JNK MAPK Signaling Pathway (p=1.0e
-4
) (Figure 22C) and Biocarta 
SRC Signaling Pathway (p=1.0e
-4
) (Figure 22D). These results are intriguing because they 
suggest that Wnt1-Early
Ex
 tumors signal through both canonical and non-canonical Wnt 
pathways to a greater extent than Wnt1-Late
Ex
 tumors. 
 
Wnt1-Early
Ex
 tumors respond to epidermal growth factor receptor inhibitors 
 In addition to canonical and non-canonical signaling, Wnt associated genes can also 
crosstalk with a variety of other signal transduction pathways [32-34], including epidermal 
growth factor receptor (EGFR) signaling [35]. Specifically, NKD2 is capable of binding and 
shuttling TGFA to the plasma membrane, which serves as an activating ligand of EGFR (Figure 
23A). Interestingly, both Nkd2 and Tgfa are higher expressed in Wnt1-Early
Ex
 tumors (FDR 0%). 
Given this observation, we hypothesized that Wnt1-Early
Ex
 tumors might have a greater degree 
of EGFR signaling than Wnt1-Late
Ex
 tumors. Consistent with this, the KEGG EGFR signaling 
pathway signature is higher expressed in Wnt1-Early
Ex
 as compared to Wnt1-Late
Ex
 tumors 
(p=0.001) (Figure 23B). To determine the clinical importance of these findings, Wnt1-Early
Ex
 
and Wnt1-Late
Ex
 tumors were randomized into one of three treatment groups: untreated, erlotinib 
(an EGFR inhibitor), or lapatinib (a duel EGFR and HER2 inhibitor). As hypothesized, Wnt1-
Early
Ex
 tumors had a median tumor regression of 90% when treated with erlotinib and a median 
tumor regression of 85% when treated with lapatinib at the end of the two week treatment period 
(Figure 23C). Wnt1-Late
Ex
 tumors, however, continued to progress with erlotinib treatment with 
a median tumor growth of 109%. When treated with lapatinib, Wnt1-Late
Ex
 tumors had a  
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Figure 23: Wnt-Early
Ex
 tumors respond to EGFR inhibitors  
A. Schematic of WNT and EGFR pathway crosstalk B. Standardized expression of the KEGG 
EGFR signaling pathway signature across mouse class. C. 14 day tumor response to Erlotinib 
and Lapatinib treatment. 
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bimodal response with about half of tumors regressing with treatment and half progressing. 
These results indicate that Wnt1-Early
Ex
 tumors were therapeutically more responsive to EGFR 
inhibitors than Wnt1-Late
Ex
 tumors. 
 
Wnt1-Early
Ex
 and Wnt1-Late
Ex
 tumors have distinct mammary subpopulation FACS 
profiles 
 Normal mammary gland physiology is supported by an underlying, complex cell 
hierarchy [4-6]. A simplistic model places the multi-potent mammary stem cell (MaSC) at the 
base of this hierarchy, having extensive, self-regenerative potential [3]. During mammary 
development, the MaSC has been proposed to divide asymmetrically to produce 
basal/myoepithelial cells as well as luminal progenitors (LumProg), which have more restricted 
proliferative and differentiation capabilities [3]. LumProg cells are capable of further 
differentiation into mature luminal (MatureLum) cells, such as Estrogen Receptor (ER)-positive 
ductal epithelium, which have an even more limited proliferative potential and some of which 
are terminally differentiated [3]. 
MMTV-Wnt1 tumors may originate from several, if not all, of the cell types within this 
mammary hierarchy. To determine if Wnt1-Early
Ex
 and Wnt1-Late
Ex
 tumors share features with 
any of these cell populations, four primary tumors from each class were fluorescence-activated 
cell sorted (FACS) using antibodies against Cd49f and Epcam [27, 36]. FACS profiles of Wnt1-
Early
Ex
 tumors consisted of two populations (Figure 24A). The major (~75%) epithelial cell 
population was Cd49f
+
/Epcam
-
, while the minor (~10%) population was Cd49f
+
/Epcam
+ 
(Figure 
24B). Normal human MaSCs are defined as having CD49f
+
/EpCAM
-
 FACS profiles [3], 
indicating that the majority of Wnt1-Early
Ex
 tumor cells share similar features as normal MaSCs.  
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Figure 24: Wnt-Early
Ex
 and Wnt1-Late
Ex
 tumors share features with different normal 
mammary cell types  
A. Cd49f, Epcam FACS profile of a representative Wnt1-Early
Ex
 tumor B. FACS population 
frequencies of Wnt1-Early
Ex
 tumors C. Cd49f, Epcam FACS profile of a representative Wnt1-
Late
Ex
 tumor D. FACS population frequencies of Wnt1-Late
Ex
 tumors E. First two principle 
components of FACS sorted Wnt1 tumors.  
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Although Wnt1-Late
Ex
 tumor FACS profiles also had two FACS populations, the frequencies 
were distinct from Wnt1-Early
Ex
 tumors (Figure 24C). Specifically, the major (~60%) epithelial 
cell population was Cd49f
+
/Epcam
+
, while the minor population (~25%) was Cd49f
+
/Epcam
-
 
(Figure 24D). Normal human LumProg cells are defined as having CD49f
+
/EpCAM
+
 FACS 
profiles [3], indicating that the majority of Wnt1-Late
Ex
 tumor cells share similar features as 
normal LumProg cells. 
It is possible that the MMTV-Wnt1 model produces semi-homogeneous tumors [29] 
simply because of intratumor variation in the frequencies of these two FACS populations and not 
because of differences between corresponding FACS populations across the two classes 
themselves. For example, this hypothesis would propose that the Wnt1-Early
Ex
 Cd49f
+
/Epcam
-
 
population should be phenotypically the same as the Wnt1-Late
Ex
 Cd49f
+
/Epam
-
 population. To 
address this, three tumors from each Wnt1 class were FACS into their corresponding populations 
and microarray analyzed. A global transcriptomic comparison of these FACS populations using a 
principle component (PC) analysis highlights that the first PC separates the Cd49f
+
/Epcam
- 
population from the Cd49f
+
/Epcam
+
 population, irrespective of which Wnt1 tumor class they 
were derived from (Figure 24E). This observation is consistent with the proposed hypothesis that 
these FACS populations are phenotypically similar across classes, but the first PC only explains 
44% of the variation. The second PC, which explains 19% of the variation, separates Wnt1-
Early
Ex
 from Wnt1-Late
Ex
 tumors. Taken together, these results indicate that while the 
corresponding FACS populations are highly similar across Wnt1-Early
Ex
 and Wnt1-Late
Ex
 
tumors, they also have class specific features. 
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Both Wnt1-Late
Ex
 tumor FACS subpopulations have tumor initiating potential 
 Given that Wnt1-Early
Ex
 tumors share features of normal MaSCs and Wnt1-Late
Ex
 
tumors share features of normal LumProg cells, we hypothesized that these two Wnt1 classes 
may have different tumor initiating potential. To test this, Wnt1 tumors were FACS sorted into 
their subpopulations and a limiting dilution assay was performed in which each subpopulation 
was injected into the mammary pad of female FVB wild-type mice. In addition, a subset of 
MMTV-Wnt1 tumors requires both FACS populations for tumor growth [27]; therefore, a third 
cohort consisting of an equal mixture of each FACS subpopulation was also performed to 
investigate this possibility in our two classes. Interestingly, Wnt1-Early
Ex
 tumor cells were 
unable to be serially transplanted into wild-type mice, giving rise to no tumors after injection 
with 50,000 cells (Figure 25). Conversely, all combinations of Wnt1-Late
Ex
 tumor cells gave rise 
to tumors. These results were unexpected, but indicate that both Wnt1-Late
Ex
 FACS 
subpopulations have tumor initiating potential. 
 Tumors that arose from the individual Wnt1-Late
Ex
 FACS populations were then re-
FACS analyzed to investigate their tumor profiles. Similar to the parental tumor, the FACS 
profile of Wnt1-Late
Ex
 Cd49f
+
/Epcam
-
 injected cells contained two populations (Figure 25B) of 
about equal frequency (Figure 25C). A similar observation was observed for Wnt1-Late
Ex
 
Cd49f
+
/Epcam
+
 injected cells (Figure 25D and 5E). These results show that both Wnt1-Late
Ex
 
populations are capable of reproducing the other population when injected into the mammary 
pad after FACS purification. 
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Figure 25: Both Wnt1-Late
Ex
 tumor subpopulations have tumor initiating potential  
A. Limiting dilution cell transplantation assay B. Cd49f, Epcam FACS profile of a representative 
Wnt1-Late
Ex
 CD49f
+
, Epcam
-
 passaged tumor. C. FACS population frequencies of Wnt1-Late
Ex
 
CD49f
+
, Epcam
-
 passaged tumors D. Cd49f, Epcam FACS profile of a representative Wnt1-
Late
Ex
 CD49f
+
, Epcam
+
 passaged tumor. E. FACS population frequencies of Wnt1-Late
Ex
 
CD49f
+
, Epcam
+
 passaged tumors.   
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Both Wnt1-Late
Ex
 tumor FACS subpopulations have activating Hras1 mutations 
 To highlight the possible genetic drivers which explain this difference in tumor initiating 
potential, five Wnt1-Early
Ex
 and five Wnt1-Late
Ex
 tumors were RNA sequenced (i.e. mRNA-
seq) to profile mutations in MMTV-Wnt1 tumors. It is known that a subset of MMTV-Wnt1 
tumors harbor activating Hras1 mutations [27]. Interestingly, all of the Wnt1-Late
Ex
 tumors 
profiled contained exon 3 activating Hras1 mutations, while none of the Wnt1-Early
Ex
 tumors 
were mutated (Figure 26A). Even though the specific mutations varied, all of the Wnt1-Late
Ex
 
Hras1 mutations resulted in an amino acid substitution at position 61, and the majority of 
samples had a mutation allele frequency of ~25% (Figure 26B). 
In colorectal cancer, APC loss of function mutations synergize with KRAS activating 
mutations to activate cancer stem cells [37]. If similar synergy occurs in Wnt1-Late
Ex
 tumors, 
these activating Hras1 mutations may explain why these tumors have tumor initiating potential. 
This hypothesis would predict that both Wnt1-Late
Ex
 FACS populations should contain Hras1 
mutations since both were capable of producing tumors when injected individually. To test this, 
DNA was extracted from each FACS population and Sanger sequenced. In support of this 
hypothesis, both Wnt1-Late
Ex
 populations contained Hras1 mutations, while both of the Wnt1-
Early
Ex
 populations were wild-type. The initial Hras1 mutations were identified from RNAseq 
data; therefore, it is possible that Wnt1-Early
Ex
 tumors could contain DNA Hras1 mutations but 
are transcriptionally repressing that allele. The Sanger sequencing data indicates that Wnt1-
Early
Ex
 tumors do not contain DNA Hras1 mutations. 
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Figure 26: Wnt-Late
Ex
 tumors have activating Hras mutations 
A. Hras1 RNAseq reads. Gray read depth corresponds to wild-type sequence. B. Hras1 exon 3 
mutations in Wnt1-Late
Ex
 tumors. 
 
 
 
  
131 
 
DISCUSSION 
 Breast cancer is the second leading cause of cancer related deaths in American women 
[38]. Patient care is particularly complicated by breast tumor heterogeneity, which is defined by 
multiple intrinsic subtypes [16-18]. While a greater understanding of tumor biology has led to 
targeted treatment options for most of these subtypes [39, 40], personalized drug targets for 
basal-like tumors remain an important unmet clinical need [41]. Given that Wnt signaling is both 
enriched in basal-like tumors and predictive of poor clinical outcomes [19], Wnt signaling has 
been proposed to be an attractive drug target for these patients [15]. The development of 
effective Wnt based therapeutics against breast tumors, however, has been slowed in part by the 
complexity of Wnt signaling [2, 15]. In addition to canonical and several non-canonical 
pathways, Wnt signaling is also known to crosstalk with a variety of other signal transduction 
pathways [32-35]. It is this context dependent nature that likely accounts for the finding that 
paracrine Wnt signaling can induce growth of some tumors and inhibit it in others [23]. Given 
the importance of Wnt signaling for regulating cell growth differentiation, and stem cell self-
renewal [15], a better understanding of these signaling pathways is needed. 
 MMTV-Wnt1 mice are an attractive model for studying the context dependent nature 
with which these aberrations influence breast tumorigenesis [27]. We recently reported that this 
model develops two subtypes of tumors by gene expression classification [29]. Given that this 
finding is underrepresented in the literature, we sought to validate our initial observation with a 
more thorough examination of these two Wnt1 subtypes. Here we definitely show that these two 
tumor subtypes are indeed phenotypically and clinically distinct, furthering our understanding of 
Wnt signaling in breast cancer. 
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 Wnt1-Early
Ex
 mice were initially characterized by their early tumor latency, accounting 
for ~60% of the MMTV-Wnt1 tumors profiled in this study. In addition to having a cellular 
dense gross pathology, these tumors were also enriched for a hypoxia gene signature. While 
these tumors contained features of both basal and luminal mammary cell types, they also have 
distinct regions that do not stain positive for either cell marker. Although the results presented 
here are unable to address the biological impact of these regions, we propose that they are likely 
to be significant given that they account for ~35% of the tumor. On a pathway level, Wnt1-
Early
Ex
 tumors have higher expression of both canonical and non-canonical signaling. On a gene 
level, Nkd2 and Tgfa were particularly highly expressed in these tumors and were capable of 
crosstalk with EGFR signaling [35]. We validated the clinical significance of this observation by 
treating MMTV-Wnt1 tumors with Erlotinib and Lapatinib. As predicted, Wnt1-Early
Ex
 tumors 
have a dynamic reduction in tumor volume after only 14 days of treatment. The FACS profile of 
these tumors highlights that they are ~75% Cd49f
+
/Epcam
-
. Although this profile is similar to 
adult mammary stem cells (MaSCs) [3], these tumors are unable to be serially transplanted into 
wild-type FVB female mice. 
 Wnt1-Late
Ex
 mice were initially identified by their longer tumor latency, accounting for 
~40% of the MMTV-Wnt1 tumors profiled in this study. These tumors have a bloody gross 
pathology, which is highlighted by the presence of ‘blood lakes’ by H&E staining. They also 
have cell features of both basal and luminal mammary cell types, which account for ~100% of 
the tumor. On a pathway level, Wnt1-Late
Ex
 tumors have high expression of canonical Wnt 
signaling compared to other mouse tumors, but lower expression in comparison to Wnt1-Early
Ex
 
tumors. Although these tumors have a FACS profile that is ~60% Cd49f
+
/Epcam
+
, they also 
contain a secondary Cd49f
+
/Epcam
- 
population that accounts for ~25% of epithelial cells. 
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Interestingly, both of these cell populations are able to reproduce tumors when serially 
transplanted into wild-type FVB female mice. Similar to the parental tumor, the FACS profile of 
these serially transplanted cells contains two populations, indicating that both Wnt1-Late
Ex
 
populations are capable to reproducing the other. This tumor initiating property may be linked to 
the presence of Hras1 mutations in Wnt1-Late
Ex
 tumors. This hypothesis is supported by the 
finding that KRAS mutations synergize with aberrant Wnt signaling in colorectal cancer to 
activate cancer stem cells [37]. In a previous publication on MMTV-Wnt1 tumors, Hras1 
mutations were shown to be specific to the Cd49f
+
/Epcam
-
 population [27], but in the tumors we 
sequenced, Hras1 mutations were identified in both the Cd49f
+
/Epcam
-
 and the Cd49f
+
/Epcam
+
 
FACS populations. This finding is also consistent with our hypothesis since we would predict 
that only cell populations with Hras1 mutations are capable of being serially passaged. Further 
testing should be aimed at addressing this possibility by introducing Hras mutations into Wnt1-
Early
Ex
 tumors and retesting their tumor initiating potential. 
 The FACS profiles imply that Wnt1-Early
Ex
 tumors arise from MaSCs and that Wnt1-
Late
Ex
 tumors arise primarily from luminal progenitor cells. Although additional experiments 
(e.g. lineage tracing) will be required to unequivocally determine this, these associations at the 
very least identify which normal mammary subpopulation a given tumor most represents in its 
current state. If the inappropriate expansion of these cell populations was truly a stochastic event, 
we would not expect to observe such a stark contrast in tumor latency between the two Wnt1 
subtypes. This latency difference suggests that these are not random, but regulated events. Of the 
tumors profiled in this study, we did not find a single case of subtype switching (where an ‘early’ 
latency tumor was classified as a ‘Wnt1-LateEx’ or vice versa), indicating that these regulating 
mechanisms are rather strong. Broadly, we hypothesize that the mechanisms governing Wnt1-
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Early
Ex
 tumor development are likely related to puberty, which occurs around this time [6]. 
Wnt1-Late
Ex
 tumor susceptibility is likely influenced by age related changes that increase the 
risk of developing Hras1 activating mutations, as is the case for KRAS mutations in colorectal 
cancer [42]. 
 
MATERIALS AND METHODS 
Mouse husbandry 
All animal work was done in UNC DLAM facilities in compliance with IACUC 
approved protocols. FVB/n mice carrying the MMTV-Wnt1 transgene were bred and housed 
until the onset of a mammary tumor. The following PCR primers were used for genotyping: 5’-
GGACTTGCTTCTCTTCTCATAGCC-3’ and 5’-CCACACAGGCATAGAGTGTCTGC-3’. 
 
Gene expression 
 Microarray gene expression data from 27 murine models of mammary carcinoma and 
normal mammary tissue were downloaded from the following gene expression omnibus (GEO) 
entries: GSE3165, GSE8516, GSE9343, GSE14457, GSE15263, GSE17916, GSE27101, and 
GSE42640 [29]. An additional 35 MMTV-Wnt1 tumors were microarray profiled as previously 
described [29]. The 420 sample dataset was normalized to correct for microarray platform bias as 
previously described [29]. 
RNAseq libraries were prepared from 26 MMTV-Wnt1 tumors using a TruSeq RNA kit 
(Illumina #RS-122-2001) before being submitted to the Lineberger Comprehensive Cancer 
Center Genomics Core to be run on the Illumina HiSeq 2000. 
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 Tumor differentiation scores were calculated across the microarray dataset as previously 
described [17]. Gene expression signatures were created for Wnt1-Early
Ex
 and Wnt1-Late
Ex
 
tumors by performing a two-class (class X versus all others or Wnt1-Early
Ex
 vs Wnt1-Late
Ex
) 
Significance Analysis of Microarrays (SAM) analysis on the microarray dataset [43]. Signatures 
were defined as all genes highly expressed in the class of interest with a false discovery rate 
(FDR) of 0%. Similarly, pathway signatures were created as previously described [29]. 
Expression scores for each gene and pathway signature were determined by calculating the 
standardized mean expression of the signature within each sample. 
  
DNA copy number 
 Genomic DNA was extracted from 11 Wnt1-Early
Ex
 and 10 Wnt1-Late
Ex
 tumors using a 
DNeasy blood and tissue kit (Qiagen #69504), labeled with a Sure Tag DNA kit (Agilent #5190-
4240), and hybridized to 244K CGH microarrays (Agilent #G4415A) as previously described 
[44]. 
The 21 sample aCGH dataset was extracted from the UNC Microarray Database as log2 
Cy5/Cy3 ratios, filtering for probes with Lowess normalized intensity values greater than ten in 
the control channel and for probes with data on greater than 70% of the microarrays [44]. The 
probes that passed these filters where then oriented in genomic order and a ten probe average 
was calculated on consecutive groups of ten probes across each chromosome, resulting in a final 
dataset of 23,204 features. A two-class (Wnt1-Early
Ex
 vs Wnt1-Late
Ex
) SAM analysis was 
performed to identify genomic regions of amplification or deletion unique to each class (FDR of 
0%). 
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Immunofluorescence 
Tissue samples were fixed in 10% neutral buffered formalin (Sigma-Aldrich 
Cat#HT5012) overnight before being submitted to the UNC Lineberger Animal Histopathology 
core facility to be paraffin embedded and sectioned. Slides were heated for 30 minutes at 55°C 
and then washed with Xylene (Fisher Scientific Cat#X3P) and ethanol (Decon Laboratories, Inc 
Cat#2716) to deparaffin the samples. To increase antigen exposure, slides were boiled for 15 
minutes in Antigen Retrieval Citra Plus Solution (BioGenex Cat#HK080-9K). Samples were 
blocked for 1 hour at room temperature in TBS (BioRad Cat#170-6435)/0.05% Tween 20 
(BioRad Cat#161-0781) plus 5% normal goat serum (Sigma- Aldrich Cat#G9023). Proteins were 
labeled with murine Krt5 (Covance Cat#PRB-160P) and murine Krt8/18 (Fitzgerald Cat#20R-
CP004) primary antibodies at 4
o
C overnight before being labeled with an anti-rabbit secondary 
antibody (Molecular Probes Cat#A11034) and anti-guinea pig (Molecular Probes Cat#A11076) 
at room temperature for one hour. Slides were mounted with DAPI (Vector Laboratories Cat#H-
1500). Slides images were taken using a Nikon Eclipse E600 microscope and processed using 
the ImageJ software. 
 
Drug Treatment 
The Wnt1-Early
Ex 
tumor with the longest latency was 13.5 weeks and the Wnt1-Late
Ex
 
tumor with the shortest latency was 16 weeks. From these observations, a 15 week cutoff was 
used to define Wnt1-Early and Wnt1-Late tumors for drug treatment analysis. MMTV-Wnt1 
tumors were randomized into treatment groups and tumor growth was monitored using two-
dimensional caliper measurements (Volume = [(width)
2
 x length]/2) [45]. Drug compounds were 
obtained from commercial sources (erlotinib from Genentech, Inc and lapatinib from 
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GlaxoSmithKline) before being synthesized into chow by OpenSource Diets to a final 
concentration of 25 mg/kg for erlotinib and 220 mg/kg for lapatinib [45]. Biological inhibitors 
were dosed continuously for two weeks. The percent change in tumor volume at the end of the 
14 day treatment period was used to quantify response. 
 
Flow cytometry 
MMTV-Wnt1 tumors were dissociated into a single cell suspension using the following 
steps. First, each tumor was manually cut into small pieces with a razor blade in 1X 
collagenase/hyaluronidase (StemCell #07919) EpiCult media (StemCell #05601) before being 
placed in a rotator for two hours at 37
o
C. Following lysis of red blood cells using ammonia 
chloride (StemCell #07850), the tumors were incubated in 1X trypsin-EDTA (Sigma #T4049) 
for five minutes at 37
o
C and then in a 1X Dispase (StemCell #07923) DNase I solution 
(StemCell #07900) for five min at 37
o
C to reduce cell clumping. Cells were filtered through a 
40µm nylon cell strainer (Fisher Scientific #08-771-1) in HBSS media (StemCell #37150) with 
10% FBS (Sigma #F2442) to obtain the final single cell suspension. To remove non-epithelial 
cells, the single cell suspension was taking through a mouse epithelial cell enrichment kit 
(StemCell #19758) following the manufacturer’s protocol. Cells were labeled with the following 
antibodies for 30 minutes at 4
o
C: FITC anti-mouse Epcam (eBioscience #11-5791-82) and APC 
anti-mouse Cd49f (eBioscience #17-0495-82). Fluorescence-activated cell sorting (FACS) was 
performed using a Beckman-Coulter CyAn ADP instrument and analyzed using the FlowJo v10 
software program. 
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Sanger Sequencing 
 Genomic DNA was extracted from the six FACS purified fractions using a DNeasy blood 
and tissue kit (Qiagen #69504) and a portion of Hras1 was PCR amplified using a Taq PCR kit 
(Qiagen Cat #201223) with the following primers: 5’-ATGGGGTATGATCCATCAGG-3’ and 
5’-CACACGGAACCTTCCTCAC-3’ (Sigma-Aldrich). PCR products were enriched with a PCR 
purification Kit (Qiagen Cat#28104) before being submitted to the UNC Genome Analysis 
Facility for Sanger sequencing. Results were analyzed using the Sequencher software. 
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CHAPTER 6: DISCUSSION
 
 
In 2014, over 230,000 women were diagnosed with new cases of breast cancer in the 
United States [1]. Given the prevalence of this disease, it is estimated that about 1 in 8 
women will develop breast cancer at some point in their life [1]. Unfortunately, these 
pessimistic statistics routinely overshadow the optimistic fact that breast cancer related 
deaths have been on the decline since the early 1990s [1]! Decreasing death rates are thought 
to be due to a combination of factors. First, there has been an increase in public awareness 
due to organizations such as Susan G. Komen which spends more than 40% of their annual 
budget on health education. This strong advocacy effort has lead to increased screening, 
which has in turn resulted in more breast tumors being caught at early stages in the 
progression process. Second, there has been an increase in breast cancer research. Between 
1930 and 1990, the death rate per 100,000 females was a little more than 30 [1]. Today, that 
rate is a little more than 20 per 100,000 females [1], about a 30% drop in 25 years! This is 
highlighted by the fact that there are about 3,000,000 breast cancer survivors living in the 
United States today [1]. 
 Improved treatment of breast cancer patients is in large part due to our increased 
understanding that breast cancer is not a single disease, but a group of diseases [2]. 
Specifically, breast cancer is defined by several therapeutic subtypes (ER
+
/HER2
-
, HER2
+
, 
and triple negative), and several related genomic subtypes called the intrinsic subtypes [2]. 
The large drop in death rate over the last 25 years [1] is due to the development of targeted 
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therapeutics against estrogen receptor positive [3] (luminal A/B [4]) and human epidermal 
growth factor receptor 2 positive [5] (HER2-enriched [4]) tumors, common subtypes of 
breast cancer. While this is great news, there are still about 40,000 breast cancer related 
deaths each year [1]. More research is therefore needed to develop therapeutics for those 
patients that do not respond to current standard-of-care. This is especially true for individuals 
with triple negative breast cancer (TNBC) (basal-like and claudin-low [4]), for whom 
targeted treatments are not a current option. 
 To develop improved therapies for TNBC, a research emphasis has been placed on 
determining the molecular drivers of basal-like and claudin-low tumors and to identify novel 
drugs that target these two subtypes. Although the genomic era promised to quickly identify 
these drug targets, it has also produced a large number of false positives. As a result of this 
and other factors, only about 5% of oncology drugs that enter clinical testing are ultimately 
approved by the FDA for use [6]. From a financial perspective, this low success rate means 
that it cost more than $1,000,000,000 of research and development spending to develop a 
single oncology drug [7]. Needless to say, improved methods are needed to streamline the 
drug development process and to lower healthcare costs. In addition, there is a great 
biological need to target TNBC given its paucity of targeted therapeutic options. 
 Genetically engineered mouse models are a biologically relevant resource for 
studying mammary cancers in vivo under genetically controlled and immune competent 
conditions and may be able to bridge this gap between bench and bedside [8]. For this to 
happen, however, the strengths and limitations of each model need to be determined so that 
the models that most faithfully represent the human condition are used preclinically. This is 
an important first step that is unfortunately overlooked by many studies. Assuming that a 
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mouse model is reflective of a given human disease state is likely to lead to mistakes when 
interpreting experimental results. For example, it should be taking into account that the 
MMTV-Neu model was identified to model luminal A tumors and not HER2-Enriched 
tumors as would easily be assumed by the nature of the model [9]. 
For these reasons, we sought in Chapter 1 to highlight those murine models that most 
faithfully mimic the human disease state on a transcriptome level, as these models are likely 
to be useful for preclinical studies [9]. To ensure our analysis included as many models as 
possible, we consolidated 27 murine models of breast carcinoma into the largest 
comprehensive genomic dataset at the time of publication [9]. It should be noted that this 
study was only able to include so many of the most widely used breast cancer models 
because of collaboration and generous donations from other researchers. From our results, we 
were able to identify eight human-to-murine counterparts and provide insight into the 
molecular pathways involved in specific human breast cancer subtypes. As expected by the 
large degree of heterogeneity of human tumors, this study shows that multiple GEMMs are 
needed to represent the diversity of human breast cancers. Importantly, there was at least one 
murine class/model for each of the six intrinsic human subtypes analyzed [9]. These reported 
trans-species associations should guide model selection during preclinical study design to 
ensure appropriate representatives of human disease subtypes are used. Lastly, this study also 
highlights a methodology to improve preclinical study designs using mouse models for any 
disease, which we suggest will increase the predictive nature of preclinical studies in mice 
[9]. 
The human-to-murine subtype associations observed in Chapter 1 could be the result 
of two interrelated possibilities. The first possibility is that both the human and murine 
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subtypes share many of the same genetic drivers. Those drivers could be influencing the 
expression of the same set of downstream genes and as a result, an association is observed 
across the two species. The second possibility is that the human and murine subtypes have 
different genetic drivers, but both drivers independently produce an expansion of the same 
mammary cell type, thus possibly reflecting transformation of a common developmental 
stage. Although tumorigenesis will influence the expression of a subset of genes within a 
cell, the majority of genes that define a given cell type are likely to remain unchanged. As a 
result, the ‘passenger’ genes that define a given cell type are driving the observed association 
across the two species. This second possibility is particularly troublesome when you consider 
that most of the oncogene-driven mouse models analyzed use either the MMTV or WAP 
promoter in their design. If the activity of these promoters varies as a function of specific 
mammary cell types, such as luminal versus myoepithelial cells, then only those cells that 
naturally use these promoters would ever give rise to a tumor in these models. This is a major 
potential caveat that unfortunately our dataset was not powered to address. 
In Chapter 2, we sought to begin addressing some of these difficult to answer 
questions concerning potential differences in developmental states. Specifically, we used 
transcriptomic profiles coming from fluorescence-activated cell sorted (FACS) normal 
mammary epithelial cell types from several independent human and murine studies to 
determine if the human-murine counterparts identified in Chapter 1 share similar normal 
epithelial cell features [10]. Using a meta-analysis approach, we derived consensus gene 
signatures for both species from normal epithelial cell types (luminal, etc) and used these to 
relate tumors to normal mammary epithelial cell phenotypes.  Through this process, we 
showed that a subset of the human-murine subtype counterparts share similar normal cell 
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features. We proposed that molecular features associated with particular cell types along the 
mammary gland cell hierarchy may contribute to the clinical heterogeneity observed in 
human breast carcinomas. To test this, we compiled a dataset of 702 neoadjuvant 
anthracycline and taxane chemotherapy treated patients to determine if these cell type 
specific gene signatures were predictive of chemotherapy response [10]. We found that both 
human luminal progenitor, as well as mouse fetal mammary stem cell features, predicted 
pathologic complete response sensitivity across all breast cancer patients treated with 
neoadjuvant chemotherapy even after controlling for intrinsic subtype, proliferation, and 
clinical variables.  
Even though targeted treatment options are improving for patients, chemotherapy still 
remains an important tool for clinicians. Chemotherapy is a devastating approach to fighting 
cancer, causing memory problems, depression, weight loss, and nausea to name a few. Being 
fully informed on the likely outcome of chemotherapy treatment is incredibly important for 
both the physician and the patient, as this information is critical when determining the next 
best treatment steps. Currently, physicians are forced to inform their patients that only about 
15-20% of breast cancer patients will completely respond to chemotherapy treatment [11]. 
While this is great news for those that completely respond, the majority of patients have 
residual disease and are left to suffer the emotional and physical side effects caused by 
chemotherapy treatment. 
The development of a robust laboratory test that can determine which tumors are 
most likely to respond to chemotherapy is greatly needed in part because it will empower 
patients to make more informed treatment decisions with their physicians. If it is determined 
that a patient has a lower chance to respond, they may not be willing to take on the side 
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effects of chemotherapy treatment for such a small chance of it working. This is particularly 
true for senior citizens who may not be as well prepared to recover from chemotherapy 
treatment as younger patients. Although more validation is required, our results identify 
several sets of good candidate genes from which to start developing this type of 
chemotherapy predictive test.  
 Even if the subset of patients that will respond to chemotherapy can be identified 
using our gene signatures, targeted treatment options promise to have fewer side effects. 
Targeted treatment options for patients with basal-like tumors remain an important unmet 
clinical need; therefore, we sought to identify novel genetic drivers of these tumors using a 
p53null mammary transplant model in Chapter 3. This model is particularly relevant because 
somatic p53 mutations are one of the most common genetic events in basal-like tumors [2]. 
Using a combination of microarray and sequencing technologies, we identified several 
candidate drivers of tumorigenesis in this mouse model of basal-like breast cancer. To 
narrow the list of candidates, a comparative analysis with human basal-like tumors was 
performed, and MET was found to be one of the most promising candidates. First, MET had 
a high Pearson correlation between its DNA copy number abundance and its gene expression 
in our mouse p53null basal-like mouse tumors only, suggesting a causal relationship. Second, 
MET is amplified in about 20% of human basal-like tumors, a conserved genetic feature 
across species. Third and possibly the most important, there is already a FDA approved drug 
that inhibits MET. Specifically, Crizotinib is approved for use in for non-small-cell lung 
cancer [12]. Only the MET amplified tumor responded to treatment, completely regressing at 
the end of the treatment period. This result suggests that Crizotinib may be effective as a 
single agent in human basal-like tumors with MET amplification. Since not all basal-like 
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patients have these aberrations, companion diagnostic tests will be required to determine 
which patients should receive treatment. The DNA amplification status of MET may serve as 
an excellent guide for treatment decisions, but proper clinical studies will be required to 
determine if that is the case. This study identifies MET as a potential driver of human basal-
like breast cancer and highlights the importance of comparative genomic studies for 
discovering novel drug targets and for determining which patient populations are most likely 
to respond to treatment. 
 In addition to MET, Wnt signaling has also been proposed to be an attractive drug 
target for the basal-like subtype given the finding that canonical Wnt signaling is both 
enriched and predictive of poor clinical outcome in these tumors [13]. The development of 
effective Wnt based therapeutics, however, has been slowed in part by a limited 
understanding of the context dependent nature with which these aberrations influence breast 
tumorigenesis. In Chapter 4, we investigated our finding from Chapter 1 that MMTV-Wnt1 
mice develop two classes of tumors that differ in tumor latency: Wnt1-Early
Ex
 and Wnt1-
Late
Ex
 [9]. To investigate the phenotypic differences between these two subtypes we used a 
combination of histology, fluorescence-activated cell sorting (FACS), limiting dilution 
assays, mutation analysis, gene expression profiling, and drug treatments. This study 
definitely shows that the MMTV-Wnt1 mouse model produces two phenotypically distinct 
subtypes of mammary tumors. Importantly, only the Wnt1-Early
Ex
 tumors responded to 
Erlotinib and Lapatinib, two EGFR inhibitors. Our results suggest that this response might be 
related to crosstalk between canonical Wnt and EGFR signaling pathways [14]. This is 
important because if similar mechanisms occur in human tumors, a subset of basal-like 
tumors may also be sensitive to these targeted drugs. 
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 In conclusion, the work presented here highlights several genetically engineered 
mouse models that are counterparts for specific human subtypes [9]. In addition to helping 
determine the molecular etiology of human breast tumors, these experiments also highlight 
several genes and pathways that may serve as attractive drug targets. These potential targets 
that were conserved between murine and human basal-like and claudin-low tumor 
counterparts are particularly interesting and important given the clinical need for targeted 
agents for these two intrinsic subtypes. Now that these human-to-murine counterparts have 
been properly identified, we hypothesize that these models should be better predictors of 
clinical trial success. As such, we propose that two types of preclinical studies using these 
mouse models should be performed simultaneously to expedite the development of improved 
therapeutic approaches. First, for drugs that are currently in clinical trials, murine studies 
should be designed to mirror these human trials. This design setup should directly inform 
their human trial counterparts. Second and possibly more important, novel drug regimens 
should also be tested using these models. This is important because while it is impractical to 
test an endless combination of drugs in proper clinical trials, a wide variety of drug 
combinations can be relatively easily tested in mice. Given that tumors are able to evade 
single-agent drug treatments through kinase reprogramming [15], these novel drug 
combinations are likely to be essential for targeting hard to treat breast tumors. If effective 
drug combinations against these murine models are discovered, proper clinical trials should 
then be performed to test the effectiveness of these treatments against human breast tumors. 
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Oncogenic PI3K mutations lead to NF-kB-dependent cytokine expression following growth 
factor deprivation 
 
Hutti JE, Pfefferle AD, Russell SC, Sircar M, Perou CM, Baldwin AS. 
 
 
Abstract: The phosphoinositide 3-kinase (PI3K) pathway is one of the most commonly 
misregulated signaling pathways in human cancers, but its impact on the tumor 
microenvironment has not been considered as deeply as its autonomous impact on tumor cells. In 
this study, we show that NF-κB is activated by the two most common PI3K mutations, PIK3CA 
E545K and H1047R. We found that markers of NF-κB are most strongly upregulated under 
conditions of growth factor deprivation. Gene expression analysis conducted on cells deprived of 
growth factors identified the repertoire of genes altered by oncogenic PI3K mutations following 
growth factor deprivation. This gene set most closely correlated with gene signatures from 
claudin-low and basal-like breast tumors, subtypes frequently exhibiting constitutive PI3K/Akt 
activity. An NF-κB-dependent subset of genes driven by oncogenic PI3K mutations was also 
identified that encoded primarily secreted proteins, suggesting a paracrine role for this gene set. 
Interestingly, while NF-κB activated by oncogenes such as Ras and EGF receptor leads to cell-
autonomous effects, abrogating NF-κB in PI3K-transformed cells did not decrease proliferation 
or induce apoptosis. However, conditioned media from PI3K mutant-expressing cells led to 
increased STAT3 activation in recipient THP-1 monocytes or normal epithelial cells in a NF-κB 
and interleukin-6-dependent manner. Together, our findings describe a PI3K-driven, NF-κB-
dependent transcriptional profile that may play a critical role in promoting a microenvironment 
amenable to tumor progression. These data also indicate that NF-κB plays diverse roles 
downstream from different oncogenic signaling pathways. 
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Cancer Cell. 2012 Jun 12;21(6):751-64. 
 
 
LKB1/STK11 inactivation leads to expansion of a pro-metastatic tumor sub-population in 
melanoma 
 
Liu W, Monahan KB, Pfefferle AD, Shimamura T, Sorrentino J, Chan K, Roadcap DW, Ollila 
DW, Nancy NE, Castrillon DH, Miller CR, Perou CM, Wong KK, Bear JE, Sharpless NE. 
 
 
Abstract: Germline mutations in LKB1 (STK11) are associated with the Peutz-Jeghers 
syndrome (PJS), which includes aberrant mucocutaneous pigmentation, and somatic LKB1 
mutations occur in 10% of cutaneous melanoma. By somatically inactivating Lkb1 with K-Ras 
activation (±p53 loss) in murine melanocytes, we observed variably pigmented and highly 
metastatic melanoma with 100% penetrance. LKB1 deficiency resulted in increased 
phosphorylation of the SRC family kinase (SFK) YES, increased expression of WNT target 
genes, and expansion of a CD24(+) cell population, which showed increased metastatic behavior 
in vitro and in vivo relative to isogenic CD24(-) cells. These results suggest that LKB1 
inactivation in the context of RAS activation facilitates metastasis by inducing an SFK-
dependent expansion of a prometastatic, CD24(+) tumor subpopulation. 
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Comparative oncogenomics implicates the Neurofibromin 1 gene (NF1) as a breast cancer driver 
 
Wallace MD, Pfefferle AD
*
, Shen L
*
, McNairn AJ, Cerami EG, Fallon BL, Rinaldi VD, 
Southard TL, Perou CM, Schimenti JC. 
 
  
Abstract: Identifying genomic alterations driving breast cancer is complicated by tumor 
diversity and genetic heterogeneity. Relevant mouse models are powerful for untangling this 
problem because such heterogeneity can be controlled. Inbred Chaos3 mice exhibit high levels of 
genomic instability leading to mammary tumors that have tumor gene expression profiles closely 
resembling mature human mammary luminal cell signatures. We genomically characterized 
mammary adenocarcinomas from these mice to identify cancer-causing genomic events that 
overlap common alterations in human breast cancer. Chaos3 tumors underwent recurrent copy 
number alterations (CNAs), particularly deletion of the RAS inhibitor Neurofibromin 1 (Nf1) in 
nearly all cases. These overlap with human CNAs including NF1, which is deleted or mutated in 
27.7% of all breast carcinomas. Chaos3 mammary tumor cells exhibit RAS hyperactivation and 
increased sensitivity to RAS pathway inhibitors. These results indicate that spontaneous NF1 
loss can drive breast cancer. This should be informative for treatment of the significant fraction 
of patients whose tumors bear NF1 mutations. 
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Combined PI3K/mTOR and MEK inhibition provides broad anti-tumor activity in faithful 
murine cancer models 
 
Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, Johnson SM, Combest AJ, Jin J, 
Zamboni WC, Perou CM, Sharpless NE. 
 
 
Abstract: Anticancer drug development is inefficient, but genetically engineered murine models 
(GEMM) and orthotopic, syngeneic transplants (OST) of cancer may offer advantages to in vitro 
and xenograft systems. We assessed the activity of 16 treatment regimens in a RAS-driven, 
Ink4a/Arf-deficient melanoma GEMM. In addition, we tested a subset of treatment regimens in 
three breast cancer models representing distinct breast cancer subtypes: claudin-low (T11 OST), 
basal-like (C3-TAg GEMM), and luminal B (MMTV-Neu GEMM). Like human RAS-mutant 
melanoma, the melanoma GEMM was refractory to chemotherapy and single-agent small 
molecule therapies. Combined treatment with AZD6244 [mitogen-activated protein-extracellular 
signal-regulated kinase kinase (MEK) inhibitor] and BEZ235 [dual phosphoinositide-3 kinase 
(PI3K)/mammalian target of rapamycin (mTOR) inhibitor] was the only treatment regimen to 
exhibit significant antitumor activity, showed by marked tumor regression and improved 
survival. Given the surprising activity of the "AZD/BEZ" combination in the melanoma GEMM, 
we next tested this regimen in the "claudin-low" breast cancer model that shares gene expression 
features with melanoma. The AZD/BEZ regimen also exhibited significant activity in this model, 
leading us to testing in even more diverse GEMMs of basal-like and luminal breast cancer. The 
AZD/BEZ combination was highly active in these distinct breast cancer models, showing equal 
or greater efficacy compared with any other regimen tested in studies of over 700 tumor-bearing 
mice. This regimen even exhibited activity in lapatinib-resistant HER2(+) tumors. These results 
show the use of credentialed murine models for large-scale efficacy testing of diverse anticancer 
regimens and predict that combinations of PI3K/mTOR and MEK inhibitors will show antitumor 
activity in a wide range of human malignancies. 
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Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA 
without affecting mammary tumor latency, gene expression or signaling 
 
Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sanchez V, Cheng H, 
Perou CM, Zhao JJ, Cook RS, Arteaga CL. 
 
 
Abstract: Mutations in PIK3CA, the gene encoding the p110α catalytic subunit of 
phosphoinositide 3-kinase (PI3K), have been shown to transform mammary epithelial cells 
(MEC). Studies suggest this transforming activity requires binding of mutant p110α via p85 to 
phosphorylated YXXM motifs in activated receptor tyrosine kinases (RTK) or adaptors. Using 
transgenic mice, we examined if ErbB3, a potent activator of PI3K, is required for mutant 
PIK3CA-mediated transformation of MECs. Conditional loss of ErbB3 in mammary epithelium 
resulted in a delay of PIK3CA(H1047R)-dependent mammary gland hyperplasia, but tumor 
latency, gene expression, and PI3K signaling were unaffected. In ErbB3-deficient tumors, 
mutant PI3K remained associated with several tyrosyl phosphoproteins, potentially explaining 
the dispensability of ErbB3 for tumorigenicity and PI3K activity. Similarly, inhibition of ErbB 
RTKs with lapatinib did not affect PI3K signaling in PIK3CA(H1047R)-expressing tumors. 
However, the p110α-specific inhibitor BYL719 in combination with lapatinib impaired 
mammary tumor growth and PI3K signaling more potently than BYL719 alone. Furthermore, 
coinhibition of p110α and ErbB3 potently suppressed proliferation and PI3K signaling in human 
breast cancer cells harboring PIK3CA(H1047R). These data suggest that PIK3CA(H1047R)-
driven tumor growth and PI3K signaling can occur independently of ErbB RTKs. However, 
simultaneous blockade of p110α and ErbB RTKs results in superior inhibition of PI3K and 
mammary tumor growth, suggesting a rational therapeutic combination against breast cancers 
harboring PIK3CA activating mutations. 
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Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to 
combinations of anti-HER2 therapies 
 
Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sanchez V, SuttonCR, Cheng H, 
Perou CM, Zhao JJ, Cook RS, Arteaga CL. 
 
 
Abstract: Human epidermal growth factor receptor 2 (HER2; ERBB2) amplification and 
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutations 
often co-occur in breast cancer. Aberrant activation of the phosphatidylinositol 3-kinase (PI3K) 
pathway has been shown to correlate with a diminished response to HER2-directed therapies. We 
generated a mouse model of HER2-overexpressing (HER2(+)), PIK3CA(H1047R)-mutant breast 
cancer. Mice expressing both human HER2 and mutant PIK3CA in the mammary epithelium 
developed tumors with shorter latencies compared with mice expressing either oncogene alone. 
HER2 and mutant PIK3CA also cooperated to promote lung metastases. By microarray analysis, 
HER2-driven tumors clustered with luminal breast cancers, whereas mutant PIK3CA tumors 
were associated with claudin-low breast cancers. PIK3CA and HER2(+)/PIK3CA tumors 
expressed elevated transcripts encoding markers of epithelial-to-mesenchymal transition and 
stem cells. Cells from HER2(+)/PIK3CA tumors more efficiently formed mammospheres and 
lung metastases. Finally, HER2(+)/PIK3CA tumors were resistant to trastuzumab alone and in 
combination with lapatinib or pertuzumab. Both drug resistance and enhanced mammosphere 
formation were reversed by treatment with a PI3K inhibitor. In sum, PIK3CA(H1047R) 
accelerates HER2-mediated breast epithelial transformation and metastatic progression, alters the 
intrinsic phenotype of HER2-overexpressing cancers, and generates resistance to approved 
combinations of anti-HER2 therapies. 
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Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular 
permeability and metastasis 
 
Harrell JC, Pfefferle AD, Zalles N, Prat A, Fan C, Khramtsov A, Olopade OI, Troester MA, 
Dudley AC, Perou CM. 
 
 
Abstract: The vasculature serves as the main conduit for breast tumor metastases and is a target 
of therapeutics in many tumor types. In this study, we aimed to determine if tumor-associated 
vascular properties could help to explain the differences observed in metastagenicity across the 
intrinsic subtypes of human breast tumors. Analysis of gene expression signatures from more 
than 3,000 human breast tumors found that genomic programs that measured vascular quantity, 
vascular proliferation, and a VEGF/Hypoxia-signature were the most highly expressed in 
claudin-low and basal-like tumors. The majority of the vascular gene signatures added 
metastasis-predictive information to immunohistochemistry-defined microvessel density scores 
and genomically defined-intrinsic subtype classification. Interestingly, pure claudin-low cell 
lines, and subsets of claudin-low-like cells within established basal-like cancer cell lines, 
exhibited endothelial/tube-like morphology when cultured on Matrigel. In vivo xenografts found 
that claudin-low tumors, but not luminal tumors, extensively perfused injected contrast agent 
through paracellular spaces and non-vascular tumor-lined channels. Taken together, the 
endothelial-like characteristics of the cancer cells, combined with both the amount and the 
physiologic state of the vasculature contribute to breast cancer metastatic progression. We 
hypothesize that the genetic signatures we have identified highlight patients that should respond 
most favorably to anti-vascular agents. 
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Oncogene. 2014 Jul 24;33(30):3992-4002. 
 
 
c-Myc and Her2 cooperate to drive stem-like phenotype with poor prognosis in breast cancer 
 
Nair R, Roden DL, Teo WS, McFarland A, Junankar S, Ye S, Nguyen A, Yang J, Nikolic I, Hui 
M, Morey A, Shah J, Pfefferle AD, Usary J, Selinger C, Baker LA, Armstrong N, Cowley MJ, 
Naylor MJ, Ormandy CJ, Lakhani SR, Herschkowitz JI, Perou CM, Kaplan W, O’Toole SA, 
Swarbrick A. 
 
 
Abstract: The HER2 (ERBB2) and MYC genes are commonly amplified in breast cancer, yet 
little is known about their molecular and clinical interaction. Using a novel chimeric mammary 
transgenic approach and in vitro models, we demonstrate markedly increased self-renewal and 
tumour-propagating capability of cells transformed with Her2 and c-Myc. Coexpression of both 
oncoproteins in cultured cells led to the activation of a c-Myc transcriptional signature and 
acquisition of a self-renewing phenotype independent of an epithelial-mesenchymal transition 
programme or regulation of conventional cancer stem cell markers. Instead, Her2 and c-Myc 
cooperated to induce the expression of lipoprotein lipase, which was required for proliferation 
and self-renewal in vitro. HER2 and MYC were frequently coamplified in breast cancer, 
associated with aggressive clinical behaviour and poor outcome. Lastly, we show that in 
HER2(+) breast cancer patients receiving adjuvant chemotherapy (but not targeted anti-Her2 
therapy), MYC amplification is associated with a poor outcome. These findings demonstrate the 
importance of molecular and cellular context in oncogenic transformation and acquisition of a 
malignant stem-like phenotype and have diagnostic and therapeutic consequences for the clinical 
management of HER2(+) breast cancer. 
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Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances 
chemosensitivity and reduces metastatic potential 
 
Knezevic J, Pfefferle AD, Petrovic I, Greene S, Perou CM, Rosen JM. 
 
 
Abstract: Claudin-low tumors are a highly aggressive breast cancer subtype with no targeted 
treatments and a clinically documented resistance to chemotherapy. They are significantly 
enriched in cancer stem cells (CSCs), which makes claudin-low tumor models particularly 
attractive for studying CSC behavior and developing novel approaches to minimize CSC therapy 
resistance. One proposed mechanism by which CSCs arise is via an epithelial-mesenchymal 
transition (EMT), and reversal of this process may provide a potential therapeutic approach for 
increasing tumor chemosensitivity. Therefore, we investigated the role of known EMT 
regulators, miR-200 family of microRNAs in controlling the epithelial state, stem-like properties 
and therapeutic response in an in vivo primary, syngeneic p53
null
 claudin-low tumor model that is 
normally deficient in miR-200 expression. Using an inducible lentiviral approach, we expressed 
the miR-200c cluster in this model and found that it changed the epithelial state, and 
consequently, impeded CSC behavior in these mesenchymal tumors. Moreover, these state 
changes were accompanied by a decrease in proliferation and an increase in the differentiation 
status. miR-200c expression also forced a significant reorganization of tumor architecture, 
affecting important cellular processes involved in cell-cell contact, cell adhesion and motility. 
Accordingly, induced miR200c expression significantly enhanced the chemosensitivity and 
decreased the metastatic potential of this p53
null
 claudin-low tumor model. Collectively, our data 
suggest that miR-200c expression in claudin-low tumors offers a potential therapeutic 
application to disrupt the EMT program on multiple fronts in this mesenchymal tumor subtype, 
by altering tumor growth, chemosensitivity and metastatic potential in vivo. 
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JNK2 prevents luminal cell commitment in normal mammary glands and tumors by inhibiting 
p53/NOTCH1 and BRCA1 expression 
 
Cantrell MA, Ebelt ND, Pfefferle AD, Perou CM, Van Den Berg CL. 
 
 
Abstract: Breast cancer is a heterogeneous disease with several subtypes carrying unique 
prognoses. Patients with differentiated luminal tumors experience better outcomes, while 
effective treatments are unavailable for poorly differentiated tumors, including the basal-like 
subtype. Mechanisms governing mammary tumor subtype generation could prove critical to 
developing better treatments. C-Jun N-terminal kinase 2 (JNK2) is important in mammary 
tumorigenesis and tumor progression. Using a variety of mouse models, human breast cancer cell 
lines and tumor expression data, studies herein support that JNK2 inhibits cell differentiation in 
normal and cancer-derived mammary cells. JNK2 prevents precocious pubertal mammary 
development and inhibits Notch-dependent expansion of luminal cell populations. Likewise, 
JNK2 suppresses luminal populations in a p53-competent Polyoma Middle T-antigen tumor 
model where jnk2 knockout causes p53-dependent upregulation of Notch1 transcription. In a p53 
knockout model, JNK2 restricts luminal populations independently of Notch1, by suppressing 
Brca1 expression and promoting epithelial to mesenchymal transition. JNK2 also inhibits 
estrogen receptor (ER) expression and confers resistance to fulvestrant, an ER inhibitor, while 
stimulating tumor progression. These data suggest that therapies inhibiting JNK2 in breast cancer 
may promote tumor differentiation, improve endocrine therapy response, and inhibit metastasis. 
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